

STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 143640

**TO: Tamthom Troung
Location: REM-5C18
Art Unit: 1624
Monday, February 07, 2005**

Case Serial Number: 10/075954

**From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556**

Noble.jarrell@uspto.gov

Search Notes

=> d his

(FILE 'HOME' ENTERED AT 11:20:28 ON 07 FEB 2005)

FILE 'HCAPLUS' ENTERED AT 11:20:35 ON 07 FEB 2005

L1 1 US20020193377/PN
E US2001-268661/AP,PRN
L2 1 US2001-268661P/AP,PRN
L3 1 L1-2

FILE 'REGISTRY' ENTERED AT 11:21:44 ON 07 FEB 2005

FILE 'HCAPLUS' ENTERED AT 11:21:46 ON 07 FEB 2005
L4 TRA L3 1- RN : 441 TERMS

FILE 'REGISTRY' ENTERED AT 11:21:48 ON 07 FEB 2005
L5 441 SEA L4

FILE 'WPIX' ENTERED AT 11:21:54 ON 07 FEB 2005

L6 1 US20020193377/PN
L7 1 US2001-268661P/AP,PRN
E US2001-268661/AP,PRN
L8 1 L6-7

=> b hcap

FILE 'HCAPLUS' ENTERED AT 11:22:40 ON 07 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 6 Feb 2005 (20050206/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d.all 13

L3 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:637660 HCAPLUS
DN 137:185501
ED Entered STN: 23 Aug 2002
TI Preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease
IN Andrianjara, Charles; Chantel-Barvian, Nicole; Gaudilliere, Bernard; Jacobelli, Henri; Ortwine, Daniel Fred; Patt, William Chester; Pham, Ly; Kostlan, Catherine Rose; Wilson, Michael William
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 264 pp.
CODEN: PIXXD2
DT Patent
LA English

IC ICM C07D239-96
 ICS C07D401-12; C07D405-12; C07D409-12; C07D405-14; C07D409-14;
 C07D471-04; C07D403-12; C07D403-10; C07D410-10; C07D413-10;
 C07D401-06; A61K031-5025; A61K031-505

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1



FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064572	A1	20020822	WO 2002-EP1979	20020211 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437122	AA	20020822	CA 2002-2437122	20020211 <--
EP 1368324	A1	20031210	EP 2002-722137	20020211 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300384	A	20031215	EE 2003-384	20020211 <--
JP 2004523546	T2	20040805	JP 2002-564505	20020211 <--
US 2002193377	A1	20021219	US 2002-75954	20020213 <--
NO 2003003593	A	20030813	NO 2003-3593	20030813 <--
PRAI US 2001-268661P	P	20010214	<--	
WO 2002-EP1979	W	20020211		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002064572	ICM	C07D239-96
	ICS	C07D401-12; C07D405-12; C07D409-12; C07D405-14; C07D409-14; C07D471-04; C07D403-12; C07D403-10; C07D410-10; C07D413-10; C07D401-06; A61K031-5025; A61K031-505
JP 2004523546	FTERM	4C063/AA01; 4C063/AA03; 4C063/BB03; 4C063/BB06; 4C063/BB08; 4C063/BB09; 4C063/CC31; 4C063/CC47; 4C063/CC58; 4C063/CC81; 4C063/CC92; 4C063/DD12; 4C063/DD28; 4C063/DD31; 4C063/EE01; 4C065/AA04; 4C065/AA05; 4C065/BB11; 4C065/CC01; 4C065/DD03; 4C065/EE02; 4C065/HH08; 4C065/JJ01; 4C065/KK01; 4C065/KK09; 4C065/LL04; 4C065/PP03; 4C065/PP07; 4C065/PP12; 4C065/QQ04; 4C065/QQ05; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC46; 4C086/BC62; 4C086/BC71; 4C086/BC73; 4C086/CB09; 4C086/GA07; 4C086/GA08; 4C086/GA09; 4C086/GA12; 4C086/MA01; 4C086/MA02; 4C086/MA03; 4C086/MA04; 4C086/MA05; 4C086/NA14; 4C086/ZA15; 4C086/ZA33; 4C086/ZA36; 4C086/ZA45; 4C086/ZA67; 4C086/ZA68; 4C086/ZA96; 4C086/ZA97; 4C086/ZB15; 4C086/ZB26; 4C086/ZC20; 4C086/ZC41; 4C086/ZC52
OS	CASREACT 137:185501; MARPAT 137:185501	
GI		

*same
US priority*



- AB Title compds. I [R1 = H, amino, alkyl, alkenyl, alkynyl, alkylamino, aryl, heterocycle, etc.; W = O, S, =N-R'; R' = alkyl, OH, CN; X1-3 = N, C-R6; R6 = H, alkyl, amino, alkylamino, etc.; Y = O, S, NH, N-alkyl; Z = O, S, NR7; R7 = H, alkyl, aryl, heteroaryl, etc.; n = 1-8; Z1 = alkyl; A = (non)aromatic, 5- or 6-membered monocycle comprising from 0 to 4 heteroatoms selected from N, O, S, etc.; m = 0-7; R2 = alkyl, halo, CN, NO2, SCF3, CF3, OCF3, etc.; R3 = H, alkyl, alkenyl, alkynyl, etc.] were prepared Over 200 synthetic examples were provided. For instance, di-Me 4-aminoisophthalate was reacted with benzylisocyanate and heated to 95-100.degree. overnight to give Me 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylate which was saponified (dioxaneaq. LiOH, reflux) to give the carboxylic acid. This intermediate was coupled with benzylamine to afford II. Selected examples of I had IC50 = 2.25 - 0.001 .mu.M for MMP13 and IC50 > 100 .mu.M for MMP1, MMP2, MMP3, MMP7, MMP9, MMP12 and MMP14; II had IC50 = 0.193 .mu.M for MMP13. Compds. I are useful for the treatment of osteoarthritis and rheumatoid arthritis.
- ST quinazoline mmp matrix metalloprotease inhibitor prepn
- IT Antiarteriosclerotics
(antiatherosclerotics; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Lung, disease
(chronic obstructive; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Heart, disease
(failure; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Intestine, disease
(inflammatory; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Eye, disease
(macula, senile degeneration; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Antiarthritics
Antiasthmatics
Antirheumatic agents
Antitumor agents
Arthritis
Asthma
Atherosclerosis
Human
Multiple sclerosis
Neoplasm
Osteoarthritis
Osteoporosis
Periodontium, disease
Psoriasis
Rheumatoid arthritis

(preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT Multiple sclerosis

Osteoporosis

(therapeutic agents; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

- IT 449208-02-0P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-pyridylmethyl)amide 449208-14-4P 449208-50-8P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-52-0P, Methyl 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449208-55-3P, 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449208-57-5P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449208-82-6P 449209-00-1P, [4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]acetic acid 449209-16-9P, Methyl 3-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-18-1P, (E)-Methyl 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]but-2-enoate 449209-20-5P, Methyl 5-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]furan-2-carboxylate 449209-22-7P, Methyl 5-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]thiophene-2-carboxylate 449209-24-9P 449209-37-4P, Methyl 2-chloro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-43-2P, Methyl 2-methoxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-44-3P, 2-Methoxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-45-4P, Methyl 2-hydroxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-47-6P, Methyl 2-methyl-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-49-8P 449209-52-3P 449209-54-5P, Methyl 4-[[6-(3-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-60-3P, 4-[[1-Methyl-6-((4-methylsulfonyl)benzyl)carbamoyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid methyl ester 449209-70-5P, 3-(4-Methoxybenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449209-75-0P, Methyl 4-[[1-methyl-2,4-dioxo-6-[[pyridin-4-ylmethyl]carbamoyl]-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-89-6P 449209-90-9P 449209-91-0P 449209-95-4P 449209-98-7P, [5-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]pyridin-2-yl]carbamic acid tert-butyl ester 449210-36-0P, 4'-[[6-((4-Methoxybenzyl)carbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]biphenyl-2-carboxylic acid methyl ester 449210-88-2P, tert-Butyl 1-[4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]cyclopropanecarboxylate 449210-90-6P, 3-Benzyl-6-benzylsulfonyl-1-methyl-1H-quinazoline-2,4-dione 449210-98-4P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid chloromethyl ester 449210-99-5P 449211-01-2P 474663-15-5P, Ethyl 2-Fluoro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate
- RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
- (MMP13 inhibitor; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT 449208-01-9P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-03-1P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide

449208-04-2P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (2-thienylmethyl)amide 449208-06-4P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (3-pyridylmethyl)amide 449208-07-5P 449208-08-6P 449208-09-7P 449208-10-0P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide 449208-11-1P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-12-2P, Methyl 4-[[[1-(3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)methanoyl]amino]methyl]benzoate 449208-13-3P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [4-hydroxy-3-methoxybenzyl]amide 449208-15-5P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-pyridylmethyl)amide 449208-16-6P, 1-Methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-20-2P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-22-4P, 3-(4-Methoxybenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-23-5P 449208-25-7P, 3-(1-(Naphth-1-yl)ethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-26-8P, 2,4-Dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-32-6P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-36-0P, 1-Methyl-2,4-dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-37-1P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-38-2P, 1-Methyl-2,4-dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-39-3P, 3-(4-Chlorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-40-6P, 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-41-7P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-42-8P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-46-2P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-47-3P, 3-Benzyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-48-4P, 3-Benzyl-1-cyclopropylmethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-49-5P, 3-Benzyl-1-isobutyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-56-4P, 1-Methyl-2,4-dioxo-3-((E)-3-phenylpropenyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-58-6P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449208-59-7P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-pyridylmethyl ester 449208-60-0P 449208-61-1P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [Benzo[1,3]dioxol-5-yl]methyl ester 449208-62-2P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [Benzo[1,3]dioxol-5-yl]methyl ester 449208-63-3P, 1-Benzyl-2,4-dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449208-64-4P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-Pyridylmethyl ester 449208-65-5P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-Pyridylmethyl ester 449208-66-6P, Benzyl 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylate 449208-67-7P, 3-Benzyl-6-methyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione 449208-69-9P, 4-Pyridylmethyl 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylate 449208-70-2P, 3-Benzyl-4-oxo-2-thioxo-1,2,3,4-

tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide
 449208-71-3P, 4-[[6-(4-Hydroxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-
 dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449208-72-4P
 449208-73-5P 449208-74-6P 449208-75-7P 449208-76-8P 449208-77-9P
 449208-78-0P 449208-79-1P 449208-80-4P 449208-81-5P 449208-83-7P
 449208-84-8P 449208-85-9P 449208-87-1P 449208-88-2P 449208-89-3P
 449208-90-6P 449208-91-7P 449208-92-8P 449208-93-9P, Ethyl
 [6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-
 3-yl]acetate 449208-94-0P 449208-95-1P, Methyl 3-[6-(4-
 methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]propionate 449208-96-2P, 3-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-
 dioxo-1,4-dihydro-2H-quinazolin-3-yl]propionic acid 449208-97-3P
 449208-98-4P, 4-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-
 dihydro-2H-quinazolin-3-yl]butyric acid 449208-99-5P, Methyl
 [4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 quinazolin-3-yl]methyl]phenyl]acetate 449209-01-2P 449209-02-3P
 449209-04-5P 449209-06-7P 449209-07-8P 449209-09-0P 449209-13-6P
 449209-14-7P 449209-17-0P, 3-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-
 dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-19-2P,
 4-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 quinazolin-3-yl]but-2-enoic acid 449209-21-6P, 5-[[6-(4-
 Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]furan-2-carboxylic acid 449209-23-8P, 5-[[6-(4-
 Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]thiophene-2-carboxylic acid 449209-25-0P 449209-26-1P
 449209-27-2P 449209-28-3P 449209-29-4P 449209-30-7P 449209-31-8P
 449209-32-9P 449209-33-0P 449209-34-1P 449209-36-3P 449209-39-6P,
 2-Chloro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-
 2H-quinazolin-3-yl]methyl]benzoic acid 449209-40-9P 449209-41-0P
 449209-46-5P, 2-Hydroxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-
 dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-48-7P,
 2-Methyl-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-
 2H-quinazolin-3-yl]methyl]benzoic acid 449209-53-4P 449209-59-0P,
 4-[[6-(3-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 quinazolin-3-yl]methyl]benzoic acid 449209-61-4P, 4-[[1-Methyl-6-(4-
 methylsulfanylbenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoic acid 449209-62-5P, 4-[[1-Methyl-2,4-dioxo-6-(4-
 (trifluoromethoxy)benzylcarbamoyl)-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoic acid methyl ester 449209-63-6P, Methyl
 4-[[6-(4-fluorobenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 quinazolin-3-yl]methyl]benzoate 449209-64-7P, 4-[[6-(4-
 Fluorobenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoic acid 449209-65-8P, Methyl 4-[[6-(benzofurazan-5-
 yl)methyl]carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoate 449209-66-9P, 4-[[6-(Benzofurazan-5-
 yl)methyl]carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoic acid 449209-67-0P, Methyl 4-[[6-(4-
 methoxybenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoate 449209-68-1P, Methyl 4-[[1-ethyl-6-(4-
 methoxybenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoate 449209-69-2P, 4-[[1-Ethyl-6-(4-
 methoxybenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoic acid 449209-71-6P, 3-(4-Hydroxybenzyl)-1-methyl-2,4-
 dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-
 yl)methyl)amide 449209-72-7P, 3-(4-Cyanobenzyl)-1-methyl-2,4-dioxo-
 1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-
 yl)methyl)amide 449209-74-9P, 1-Methyl-2,4-dioxo-3-(3-(pyridin-4-
 yl)propenyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid
 ((pyridin-4-yl)methyl)amide 449209-76-1P, 4-[[1-Methyl-2,4-dioxo-6-
 [(pyridin-4-yl)methyl]carbamoyl]-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoic acid hydrochloride 449209-77-2P, Methyl
 [4-[[1-methyl-2,4-dioxo-6-[(pyridin-4-yl)methyl]carbamoyl]-1,4-dihydro-2H-
 quinazolin-3-yl]methyl]phenyl]acetate 449209-78-3P, [4-[[1-Methyl-2,4-
 dioxo-6-[(pyridin-4-yl)methyl]carbamoyl]-1,4-dihydro-2H-quinazolin-3-

yl)methyl]phenyl]acetic acid hydrochloride 449209-79-4P 449209-80-7P
 449209-81-8P, Methyl [6-[(1,3-Benzodioxol-5-yl)methyl]carbamoyl]-3-benzyl-
 2,4-dioxo-1,4-dihydro-2H-quinazolin-1-yl]acetate 449209-82-9P,
 [6-[(1,3-Benzodioxol-5-yl)methyl]carbamoyl]-3-benzyl-2,4-dioxo-3,4-dihydro-
 2H-quinazolin-1-yl]acetic acid 449209-83-0P, Methyl 4-[[6-[(1,3-
 benzodioxol-5-yl)methyl]carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 quinazolin-3-yl]methyl]benzoate 449209-84-1P, 4-[[6-[(1,3-Benzodioxol-5-
 yl)methyl]carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoic acid 449209-85-2P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid (4-(sulfamoyl)benzyl)amide
 449209-86-3P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid [3-(pyridin-4-ylsulfanyl)propyl]amide 449209-87-4P,
 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic
 acid (4-morpholin-4-ylbutyl)amide 449209-88-5P 449209-92-1P,
 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic
 acid (4-((dimethylcarbamoyl)methoxy)benzyl)amide 449209-93-2P
 449209-94-3P 449209-96-5P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid (4-(dimethylcarbamoyl)benzyl)amide
 449209-97-6P 449209-99-8P 449210-00-8P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-
 tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-
 yl)methyl]amide 449210-01-9P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-
 tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-
 yl)methyl]amide 449210-03-1P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-
 yl)methyl]amide 449210-07-5P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-
 2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoic acid
 449210-11-1P 449210-12-2P 449210-13-3P, 3-Benzyl-1-methyl-2,4-dioxo-
 1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid
 [benzo[1,3]dioxol-5-yl)methyl]amide 449210-20-2P, Methyl
 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoate 449210-23-5P, tert-Butyl
 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoate 449210-24-6P,
 4-[[6-(3-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoic acid 449210-27-9P
 449210-28-0P, 3-Benzyl-1-methyl-6-(3-phenylpropionyl)-1H-quinazoline-2,4-
 dione 449210-29-1P 449210-30-4P 449210-31-5P, 3-Benzyl-1-methyl-6-[2-
 (pyridin-4-ylsulfanyl)acetyl]-1H-quinazoline-2,4-dione 449210-32-6P
 449210-33-7P 449210-34-8P 449210-37-1P, 4'-[[6-(4-
 Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]biphenyl-2-carboxylic acid 449210-39-3P, 2-Fluoro-4-[[6-(4-
 methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoic acid 449210-40-6P, 2-Methoxy-4-[[6-(4-
 methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-
 yl]methyl]benzoic acid 2-dimethylaminoethyl ester 449210-41-7P,
 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 quinazolin-3-yl]methyl]-2-methylbenzoic acid 2-dimethylaminoethyl ester
 449210-42-8P 449210-43-9P, [4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-
 dioxo-1,4-dihydro-2H-quinazolin-3-yl]phenyl]acetic acid 449210-45-1P,
 1-Methyl-3-(1-(naphthalen-1-yl)ethyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-yl)methyl]amide
 449210-47-3P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-
 dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoic acid 449210-49-5P,
 3-(3-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((pyridin-4-yl)methyl)amide 449210-51-9P,
 3-(3-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-52-0P,
 3-(3-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((pyridin-3-yl)methyl)amide 449210-53-1P 449210-54-2P
 449210-55-3P, 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide
 449210-56-4P, 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid ((pyridin-3-yl)methyl)amide
 449210-57-5P 449210-61-1P, 3-(4-Bromobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-

tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-62-2P, 3-(3,4-Difluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridin-3-ylmethyl)amide 449210-66-6P, 3-(3,4-Difluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridin-4-ylmethyl)amide 449210-67-7P 449210-68-8P, 3-(3-Chloro-4-fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449210-72-4P 449210-73-5P 449210-74-6P 449210-75-7P 449210-76-8P, 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449210-78-0P, 3-(4-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449210-79-1P, 3-(4-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-3-yl)methyl)amide 449210-81-5P, 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-3-yl)methyl)amide 449210-82-6P 449210-84-8P 449210-85-9P, 3-(4-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-87-1P, 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-89-3P, 1-[4-[[6-(4-Methoxybenzyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]cyclopropanecarboxylic acid 449210-92-8P, 3-Benzyl-1-methyl-6-((phenylmethyl)sulfinyl)-1H-quinazoline-2,4-dione 449210-93-9P, 3-Benzyl-1-methyl-6-((phenylmethyl)sulfonyl)-1H-quinazoline-2,4-dione 449210-94-0P 449210-95-1P, 4-[[6-(4-Methoxybenzyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazoline-3-yl]methyl]benzoic acid 3-(dimethylamino)-2,2-dimethylpropyl ester 449210-96-2P, 4-[[6-((4-Methoxybenzyl)carbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazoline-3-yl]methyl]benzoic acid 2-(dimethylamino)-2-methylpropyl ester 449210-97-3P, 4-[[6-(4-Methoxybenzyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazoline-3-yl]methyl]benzoic acid 2-dimethylaminoethyl ester 449211-00-1P 449211-04-5P 449211-08-9P 449211-12-5P, 4-[[6-((3-Methoxybenzyl)carbamoyl)methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid methyl ester 449211-14-7P, 4-[[1-Ethyl-2,4-dioxo-6-((4-(trifluoromethoxy)benzyl)carbamoyl)-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid methyl ester 449211-16-9P, 4-[[1-Methyl-2,4-dioxo-6-[[pyridin-4-ylmethyl]carbamoyl]-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449211-18-1P, [4-[[1-Methyl-2,4-dioxo-6-[[pyridin-4-ylmethyl]carbamoyl]-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]acetic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MMP13 inhibitor; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT 4315-09-7P, 4-Nitroisophthalic acid 23965-06-2P, 3-Benzyl-6-bromo-1H-quinazoline-2,4-dione 33857-88-4P 63746-12-3P, Dimethyl 4-aminoisophthalate 69048-70-0P, Dimethyl 4-nitroisophthalate 69209-73-0P 151979-21-4P, 5-Iodo-2-((methyl)amino)benzoic acid 177913-48-3P, Dimethyl 4-amino-1-hydroxycyclohexa-3,5-diene-1,3-dicarboxylate 184681-83-2P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 209604-61-5P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 221540-53-0P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 342644-48-8P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 449207-91-4P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449207-92-5P 449207-93-6P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carbonitrile 449207-94-7P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449207-95-8P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449207-96-9P, 1-Methyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-

carboxylic acid 449207-97-0P, 3-(3-Fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449207-98-1P, 1-Methyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449207-99-2P, 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-00-8P, 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-17-7P, 2,4-Dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-18-8P, 2,4-Dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-19-9P, 2,4-Dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-21-3P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-24-6P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-methoxybenzyl)amide 449208-27-9P, Dimethyl 4-(N'-((pyridin-4-yl)methyl)ureido)isophthalate 449208-29-1P, 2,4-Dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-31-5P, 2,4-Dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-33-7P 449208-34-8P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-35-9P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-43-9P 449208-44-0P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-45-1P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-51-9P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-53-1P 449208-68-8P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 449209-10-3P, 3-(4-Chlorosulfonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-11-4P, 3-(4-Dimethylsulfonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-12-5P, 3-(4-Dimethylsulfonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-15-8P, 1-Methyl-3-(4-methylsulfonylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-50-1P, 2,4-Dioxo-1-methyl-3-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-51-2P, 2,4-Dioxo-1-methyl-3-(pyridine-4-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-55-6P, 3-(4-Methoxycarbonylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449209-57-8P, 3-(4-Methoxycarbonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449209-58-9P, 3-(4-Methoxycarbonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-73-8P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridin-4-ylmethyl)amide 449210-02-0P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid 449210-04-2P 449210-05-3P 449210-06-4P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 449210-08-6P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 449210-09-7P 449210-10-0P, Methyl 4-[[6-(4-Methoxybenzyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoate 449210-14-4P, 1-Benzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxaldehyde 449210-15-5P 449210-16-6P 449210-17-7P 449210-18-8P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid methyl ester 449210-19-9P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid 449210-21-3P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid 449210-22-4P 449210-25-7P 449210-26-8P, tert-Butyl 4-[[6-(3-Methoxybenzyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoate 449210-58-6P, 3-(4-Bromobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-59-7P,

1-Methyl-3-(4-bromobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-60-0P, 1-Methyl-3-(4-bromobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449210-63-3P, 3-(3,4-Difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-64-4P, 1-Methyl-3-(3,4-difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-65-5P, 1-Methyl-3-(3,4-difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449210-69-9P, 3-(3-Chloro-4-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-70-2P, 1-Methyl-3-(3-chloro-4-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-71-3P, 1-Methyl-3-(3-chloro-4-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449210-77-9P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridazin-4-ylmethyl)amide 449210-80-4P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridin-3-ylmethyl)amide 449210-83-7P 449210-86-0P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-91-7P, 3-Benzyl-6-iodo-1-methyl-1H-quinazoline-2,4-dione

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT 9001-12-1, MMP-1 9004-06-2, MMP-12 79955-99-0, MMP 3 141256-52-2, MMP 7 146480-35-5, MMP-2 146480-36-6, MMP-9 161384-17-4, MMP-14 175449-82-8, MMP-13

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT 78-73-9, Choline bicarbonate 78-77-3, Isobutyl bromide 79-07-2, 2-Chloroacetamide 96-32-2, Methyl bromoacetate 96-33-3, Methyl acrylate 100-11-8, 4-Nitrobenzyl bromide 100-44-7, Benzyl chloride, reactions 100-46-9, Benzylamine, reactions 100-51-6, Benzyl alcohol, reactions 104-84-7, 4-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine 105-36-2, Ethyl bromoacetate 105-39-5, Ethyl 2-chloroacetate 106-95-6, Allyl bromide, reactions 106-96-7, Prop-2-ynyl bromide 108-00-9, N,N-Dimethylethylene diamine 108-01-0, 2-(Dimethylamino)ethanol 119-68-6, N-Methylanthranilic acid 138-39-6, 4-(Aminomethyl)benzenesulfonamide 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl acrylate 332-48-9, 2-(4-Fluorophenoxy)ethyl bromide 351-52-0, 4-Chloromethyl-2-fluoro-1-methoxybenzene 459-46-1 495-76-1, Piperonyl alcohol 540-51-2, 2-Bromoethanol 586-95-8, 4-Pyridylcarbinol 593-71-5, Chloroiodomethane 622-78-6, Benzyl isothiocyanate 622-95-7, 4-Chlorobenzyl bromide 637-59-2, 3-Phenylpropyl bromide 870-63-3, 1-Bromo-3-methylbut-2-ene 874-89-5, 4-Hydroxymethylbenzonitrile 874-98-6, 3-(Bromomethyl)-1-methoxyphenyl 938-09-0, 2-Chloroethyl phenyl sulfone 1117-71-1, Methyl 4-bromocrotonate 1129-28-8, Methyl 3-(bromomethyl)benzoate 1943-82-4, Phenethyl isocyanate 2144-37-8, Methyl 5-(chloromethyl)-2-furoate 2393-23-9, 4-Methoxybenzylamine 2417-72-3, Methyl 4-(bromomethyl)benzoate 2550-36-9, (Bromomethyl)cyclohexane 2620-50-0, Piperonylamine 2969-81-5, Ethyl 4-bromobutyrate 3113-72-2, 5-Methyl-2-nitrobenzoic acid 3173-56-6, Benzyl isocyanate 3277-89-2, Phenethylmagnesium bromide 3395-91-3, Methyl 3-bromopropanoate 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1, 4-Picolylamine 4070-48-8 4637-24-5 5071-96-5, 3-Methoxybenzylamine 5586-89-0 5794-88-7, 2-Amino-5-bromobenzoic acid 6232-11-7, Methyl 4-(aminomethyl)benzoate hydrochloride 6321-07-9, 4-Morpholin-4-ylbutylamine 6482-24-2, 1-Bromo-2-methoxyethane 7005-47-2, 2-(Dimethylamino)-2-methylpropanol 7051-34-5, Cyclopropylmethyl bromide 7149-10-2, 4-Hydroxy-3-methoxybenzylamine hydrochloride 7398-42-7, Methyl 4-(bromomethyl)phenylacetate 10406-25-4 13734-41-3 17201-43-3, 4-(Bromomethyl)benzonitrile 18469-52-8, Methyl 4-aminomethyl benzoate 19059-68-8, 3-(Dimethylamino)-2,2-dimethylpropanol

22059-22-9, N-Hydroxyacetamide 22600-30-2, Methyl 5-amino-2-furan
 carboxylate 25589-18-8, 3-Benzyl-6-methyl-1H-pyrimidine-2,4-dione
 26146-77-0, (E)-Cinnamyl bromide 27757-85-3, 2-Thienylmethylamine
 28188-41-2, 3-(Bromomethyl)benzonitrile 30260-66-3, Dimethylhydrazine
 30280-44-5, 4-Chlorobenzyl isocyanate 32863-31-3, 5-
 Bromomethylbenzofurazan 39077-96-8 40724-47-8, 4-
 Bromomethylbenzenesulfonamide 41886-04-8, 3-Bromomethyl-1-
 methylpiperidine 50541-93-0, 4-Amino-1-benzylpiperidine 55401-97-3,
 2-(Bromomethyl)pyridine 56651-60-6, 4-Methoxybenzyl isocyanate
 69966-55-8, 3-(Bromomethyl)pyridine 72235-53-1, 3,4-Difluorobenzylamine
 72235-56-4, 3-Chloro-4-fluorobenzylamine 74733-27-0, Methyl
 4-bromomethyl-2-methoxybenzoate 74733-28-1, Methyl 4-bromomethyl-2-
 methyl benzoate 78358-86-8, 1-(2-Bromoethyl)pyrrole 78826-46-7,
 (tert-Butoxy)acetyl chloride 83171-39-5, 4-Methylthiobenzylamine
 85070-57-1, Methyl 4-(bromomethyl)-2-fluorobenzoate 85147-14-4
 88442-63-1, 1-(1-Naphthyl)ethyl isocyanate 89583-07-3,
 4-(2-Bromoethyl)morpholine 93919-56-3, 4-Trifluoromethoxybenzylamine
 99067-96-6, (4-(Dimethylamino)benzyl)isocyanate 102422-56-0,
 3-Fluorobenzyl isocyanate 108052-76-2, tert-Butyl 4-bromomethylbenzoate
 108499-32-7, Methyl 5-bromomethylthiophene-2-carboxylate 114772-38-2
 114772-54-2, 2-(4-Bromomethylphenyl)benzonitrile 120788-70-7, Ethyl
 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-
 carboxylate 128674-45-3, 4-(3-Chloropropenyl)pyridine hydrochloride
 138402-33-2 138895-24-6, 6-Amino-3-benzyl-1H-pyrimidine-2,4-dione
 148900-69-0 154470-79-8, Methyl 1,3-dimethyl-2,4-dioxo-1,2,3,4-
 tetrahydropyrido[3,4-d]pyrimidine-6-carboxylate 155965-45-0
 220875-89-8, 5-(4-Chloromethylphenyl)-1-methyl-1H-tetrazole 221031-44-3,
 2-Chloro-1-(4-diethylaminophenyl)ethan-1-one 302912-23-8, 4-Bromobenzyl
 isocyanate 304873-96-9, tert-Butyl (5-bromomethylpyridin-2-yl)carbamate
 448965-87-5, tert-Butyl 1-(4-bromomethylphenyl)cyclopropanecarboxylate
 449208-54-2, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic
 acid 449209-03-4, 3-((E)-3-Chloropropenyl)pyridine 449209-05-6,
 4-((E)-3-Chloropropenyl)pyridine 449209-08-9, 3-(4-
 (Methanesulfonyl)benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-
 6-carboxylic acid 449209-35-2, 3-(4-Chloromethylphenyl)-5-
 methyl[1,2,4]oxadiazole 449209-38-5, Methyl 2-chloro-4-
 chloromethylbenzoate 449209-42-1, 5-(4-Chloromethylphenyl)-2-methyl-2H-
 tetrazole 449209-56-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant: preparation of quinazolines as specific inhibitors of type-13
 matrix metalloprotease)

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Abou-Hadeed, K: PTERIDINES 1996, V7(4), P113 HCAPLUS
- (2) Anon: AMBINTER: EXPLORATORY LIBRARY 2002
- (3) Anon: CHEMSTAR PRODUCT LIST 2001
- (4) Anon: SCIENTIFIC EXCHANGE PRODUCT LIST 2001
- (5) Anon: SCREENING COLLECTION 2000
- (6) Bemis, G: WO 9964400 A 1999 HCAPLUS
- (7) Brittelli, D: WO 9743239 A 1997 HCAPLUS
- (8) Chen, J: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 2000, V122, P9648 HCAPLUS
- (9) Ciba Geigy Ag: DE 2441959 A 1975 HCAPLUS
- (10) Ghose, A: J MED CHEM 1984, V27(7), P901 HCAPLUS
- (11) Kim, Y: CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, PROCEEDINGS
 OF THE INTERNATIONAL SYMPOSIUM ON PTERIDINES AND FOLATES, 11TH 1997, P41
 MEDLINE
- (12) Lespagnol, A: BULL SOC PHARM LILLE 1977, V33(1), P67 HCAPLUS
- (13) Liverton, N: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1998, V8(5), P483
 HCAPLUS
- (14) Murata, S: CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997,
 PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON PTERIDINES AND FOLATES, 11TH
 1997, P17 HCAPLUS
- (15) Nesterov, SU 119879 A 1959 HCAPLUS
- (16) Ogawa, H: CHEM PHARM BULL 1988, V36(6), P2253 HCAPLUS

- (17) Reiter, L: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1999, V9(2), P127
HCAPLUS
(18) Sladowska, H: FARMACO, ED SCI 1986, V41(12), P954 HCAPLUS

=> b wpix

FILE 'WPIX' ENTERED AT 11:22:53 ON 07 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 2 FEB 2005 <20050202/UP>
MOST RECENT DERWENT UPDATE: 200508 <200508/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF
HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

>>> SMILES and ISOSMILES strings are no longer available as
Derwent Chemistry Resource display fields <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>
FOR DETAILS. <<<

=> d all 18

L8 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2002-740698 [80] WPIX
DNC C2002-209675
TI New quinazolines useful in the treatment of e.g. arthritis, multiple
sclerosis, periodontal disease, inflammatory bowel disease, and psoriasis.
are matrix metalloproteinase inhibitors.
DC B02
IN ANDRIANJARA, C; BARVIAN, N C; GAUDILLIERE, B; JACOBELLI, H; KOSTLAN, C R;
ORTWINE, D F; PATT, W C; PHAM, L; WILSON, M W; CHANTEL-BARVIAN, N
PA (WARN) WARNER LAMBERT CO LLC; (ANDR-I) ANDRIANJARA C; (BARV-I) BARVIAN N
C; (GAUD-I) GAUDILLIERE B; (JACO-I) JACOBELLI H; (KOST-I) KOSTLAN C R;
(ORTW-I) ORTWINE D F; (PATT-I) PATT W C; (PHAM-I) PHAM L; (WILS-I) WILSON
M W; (WARN) WARNER LAMBERT CO
CYC 101
PI WO 2002064572 A1 20020822 (200280)* EN 64 C07D239-96
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

ZW

US 2002193377	A1 20021219 (200303)	C07D487-02	<--
NO 2003003593	A 20030813 (200373)	C07D239-96	
EP 1368324	A1 20031210 (200382)	C07D239-96	EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU LV MC MK NL PT
RO SE SI TR

KR 2003074827	A 20030919 (200409)	C07D405-12	
HU 2003003164	A2 20040128 (200415)	C07D239-96	
AU 2002253070	A1 20020828 (200427)	C07D239-96	
JP 2004523546	W 20040805 (200451)	C07D239-96	445
SK 2003001001	A3 20040908 (200462)	C07D239-96	
CZ 2003002142	A3 20041215 (200501)	C07D239-96	
CN 1537105	A 20041013 (200508)	C07D239-96	

ADT WO 2002064572 A1 WO 2002-EP1979 20020211; US 2002193377 A1
Provisional US 2001-268661P 20010214; US 2002-75954 20020213; NO
2003003593 A WO 2002-EP1979 20020211; NO 2003-3593 20030813; EP 1368324 A1
EP 2002-722137 20020211; WO 2002-EP1979 20020211; KR 2003074827 A KR
2003-710659 20030813; HU 2003003164 A2 WO 2002-EP1979 20020211; HU
2003-3164 20020211; AU 2002253070 A1 AU 2002-253070 20020211; JP
2004523546 W JP 2002-564505 20020211; WO 2002-EP1979 20020211; SK
2003001001 A3 WO 2002-EP1979 20020211; SK 2003-1001 20020211; CZ
2003002142 A3 WO 2002-EP1979 20020211; CZ 2003-2142 20020211; CN 1537105 A
CN 2002-805014 20020211

FDT EP 1368324 A1 Based on WO 2002064572; HU 2003003164 A2 Based on WO
2002064572; AU 2002253070 A1 Based on WO 2002064572; JP 2004523546 W Based
on WO 2002064572; SK 2003001001 A3 Based on WO 2002064572; CZ 2003002142
A3 Based on WO 2002064572

PRAI US 2001-268661P 20010214; US 2002-75954
20020213

IC ICM C07D239-96; C07D405-12; C07D487-02

ICS A61K031-5025; A61K031-505; A61K031-517; A61K031-519; A61K031-525;
A61K031-5377; A61P001-02; A61P001-04; A61P009-04; A61P009-10;
A61P011-00; A61P011-06; A61P017-06; A61P019-00; A61P019-02;
A61P019-10; A61P025-28; A61P027-02; A61P029-00; A61P035-00;
A61P043-00; C07D239-72; C07D239-95; C07D401-06; C07D401-12;
C07D403-10; C07D403-12; C07D405-06; C07D405-14; C07D409-06;
C07D409-12; C07D409-14; C07D410-10; C07D413-06; C07D413-10;
C07D471-04

AB WO 2002064572 A UPAB: 20021212
NOVELTY - Quinazolines are new.
DETAILED DESCRIPTION - Quinazolines of formula (I), their racemic,
isomers, N-oxides, or salts are new.
R1 = H, amino, T, 3-6C alkenyl, 3-6C alkynyl, mono or di-T-amino-T,
aryl, aryl-T, heterocycle, or 3-6 membered cycloalkyl-T (all optionally
substituted by at least one amino, T, cyano, halo-T, C(O)OR4, OR4 or SR4);
T = 1-6C alkyl
R4 = H or T;
W = O, S, or a group NR';
R' = T, hydroxyl, or cyano;
X1 - X3 = N or CR6;
R6 = H, T, amino, mono or di-T-amino, hydroxyl, 1-6C alkoxy, or
halo;
Y = O, S, NH, or N-T;
Z = O, S, or NR7;
R7 = H, T, aryl-T, cycloalkyl, or (hetero)aryl;
n = 1-8;
Z1 = CR8R9;
R8 and R9 = H, T, halo-T, halo, amino, OR4, SR4 or C(O)OR4;
A = 5 or 6 membered optionally aromatic monocycle containing 0-4 N, O
or S, or bicycle, composed of two aromatic or non-aromatic, 5 or 6
membered rings, containing 0-4 N, O, or S;
m = 0-7;
R2 = T, halogen, CN, NO2, SCF3, CF3, OCF3, NR10R11, OR10, SR10,
SOR10, SO2R10, (CH2)KS02NR10OR11, X5(CH2)kC(O)OR10, (CH2)kC(O)OR10,

X5(CH2)kC(O)NR10R11, (CH2)kC(O)NR10R11, X4R12;

X5 and X7 = O, or S optionally substituted by 1 or 2 O, or N substituted by H or T;

k = 0-3;

R10 and R11 = H or T;

X4 and X6 = single bond, CH2, or X5;

R12 = 5 or 6 membered ring (optionally substituted by at least one of T, halo, hydroxyl and amino;

R3 = H, T, 3-6C alkenyl, 3-6C alkynyl (optionally substituted by at least one of amino, cyano, halo-T, cycloalkyl, C(=O)NR10R11, C(=O)OR10, OR10, and SR10;

R10 and R11 = H, T, or (R5)-B-(Z2)p;

p = 0-8;

Z2 = CR13R14;

R13 and R14 = H, T, phenyl, halo-T, halo, amino, OR4, SR4 or C(=O)OR4;

R4 and R15 - R17 = H or T,

B = 5 or 6 membered monocycle containing 0-4 N O, or S, bicycle, composed of 5 or 6 membered rings containing 0-4 N, O, or S;

q = 0-7;

R5 = T, halogen, CN, NO2, CF3, OCF3, (CH2)kNR15R16, N(R15)C(O)R16, N(R15)C(O)OR16, N(R15)SO2R16, N(SO2R1)R15)2, OR15, S(O)k1R15, SO2NR16R17, (CH2)k2NR15R16, (CH2)kSO2NR15R16, X7(CH2)kC(O)OR15, (CH2)kC(O)OR16, C(O)O(CH2)k2NR15R16, C(O)O(CH2)k2C(O)OR18, X7(CH2)kC(O)NR15R16, (CH2)kC(O)NR15R16, R19C(O)OR15, X6R20, or C(O)-R21NR15R16;

k = 0-3;

k1 = 0-2;

k2 = 1-4;

R18 = 1-6C alkyl, R21NR15R16, -R21R15C(O)R21NR15R16, or C(O)OR21NR15R16;

R21 = 1-6C alkylene group;

R19 = 3-6C cycloalkyl group;

R20 = 5 or 6 membered ring (optionally substituted by at least one of 1-6C alkyl, halo, OH, oxo, cyano, tetrazole, amino, and C(O)OR4.

Provided that:

(1) When n at least 2 then the hydrocarbon chain Z1 and Z2 optionally contains at least one multiple bond and/or one of the carbon atoms in the hydrocarbon chain Z1 and Z2 may be replaced with X5;

(2) When one of the carbon atoms in the hydrocarbon chain Z1 is replaced with S (optionally substituted by 1 or 2 O), then the group C(=Y)Z optionally may be absent in (I);

(3) R12 is heterocyclic ring then it contains 1-4 of S, O, or N; and

(4) when X1 is N, then X2 is other than a carbon atom substituted with a methyl group or NH-CH3.

INDEPENDENT CLAIMS are included for the following:

(a) Intermediate of formulae (III) or (IV); and

(b) Six methods for the preparations of (I).

ACTIVITY - Antirheumatic; Antiarthritic; Osteopathic;

Antiinflammatory; Psoriatic; Neuroprotective; Cardiant;

Antiarteriosclerotic; Asthmatic; Cytostatic.

MECHANISM OF ACTION - Matrix metalloprotease (MMP)-13 inhibitor.

A reaction contained (4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid (50 mM), CaCl2 (10 mM), pH 7, room temperature, 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) (1 mM), thiopeptolide substrate Ac-Pro-Leu-Gly-thioester-Leu-Leu-Gly, Ethanol (100 micro M), inhibitor in 2% dimethylsulfoxide and human collagenase-3 catalytic domain enzyme (2.5 nM), 4(6-(4-Methoxy-benzylcarbamoyl)-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-ylmethyl)-benzoate (A) was screened from 100 micro M - 0.5 nM. The change in the absorbance at 405 nm was monitored on microplate reader at room temperature for 10-15 minutes. (A) showed IC50 value 0.001 micro M.

USE - In the preparation of medical product for treating a disease or therapy involving inhibition of type-13 matrix metalloprotease e.g. arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal

disease, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age related muscular degeneration and cancer (all claimed).

ADVANTAGE - (I) have selective and high inhibition activity for matrix metalloprotease-13.

Dwg.0/0

FS CPI

FA AB: GI; DCN

MC CPI: B06-H; B14-C09; B14-D07C; B14-E10C; B14-F01; B14-F07; B14-H01;
B14-K01; B14-N01; B14-N03; B14-N06B; B14-N17; B14-S01

=> b home

FILE 'HOME' ENTERED AT 11:23:05 ON 07 FEB 2005

=>

=> b reg

FILE 'REGISTRY' ENTERED AT 11:47:06 ON 07 FEB 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7
 DICTIONARY FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que sta l15

L13 STR



VAR G1=N/O/S

REP G2=(0-1) AK

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

L15 7 SEA FILE=REGISTRY SSS FUL L13

100.0% PROCESSED 31 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

=> d his

(FILE 'HOME' ENTERED AT 11:20:28 ON 07 FEB 2005)

FILE 'HCAPLUS' ENTERED AT 11:20:35 ON 07 FEB 2005

L1 1 US20020193377/PN
 E US2001-268661/AP,PRN
 L2 1 US2001-268661P/AP,PRN
 L3 1 L1-2

FILE 'REGISTRY' ENTERED AT 11:21:44 ON 07 FEB 2005

L4 FILE 'HCAPLUS' ENTERED AT 11:21:46 ON 07 FEB 2005
TRA L3 1- RN : 441 TERMS

L5 FILE 'REGISTRY' ENTERED AT 11:21:48 ON 07 FEB 2005
441 SEA L4

L6 FILE 'WPIX' ENTERED AT 11:21:54 ON 07 FEB 2005
L7 1 US20020193377/PN
1 US2001-268661P/AP,PRN
E US2001-268661/AP,PRN
L8 1 L6-7

L9 FILE 'REGISTRY' ENTERED AT 11:35:05 ON 07 FEB 2005
L10 STR
0 L9
L11 STR L9
L12 0 L11
L13 STR L11
L14 0 L13
L15 7 L13 FULL
SAV TEM L15 TRU954F0/A

L16 FILE 'HCAPLUS' ENTERED AT 11:45:42 ON 07 FEB 2005
4 L15

L17 FILE 'HCAOLD' ENTERED AT 11:45:49 ON 07 FEB 2005
0 L15

=> b hcap

FILE 'HCAPLUS' ENTERED AT 11:47:20 ON 07 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 6 Feb 2005 (20050206/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr l16 1-2

L16 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:60320 HCAPLUS
DN 140:105336
ED Entered STN: 26 Jan 2004
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use
IN Roark, William Howard
PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl.. 239 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-519
 ICS A61K031-00; A61P019-02; A61P009-00
 CC 1-12 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004006931	A2	20040122	WO 2003-IB3098	20030707
	WO 2004006931	A3	20040513		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004019054	A1	20040129	US 2003-619769	20030715
PRAI	US 2002-396785P	P	20020717		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004006931	ICM	A61K031-519
	ICS	A61K031-00; A61P019-02; A61P009-00

OS MARPAT 140:105336

AB The invention provides a combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib, and their use for the treatment of diseases that are responsive to inhibition of MMP-13 and cyclooxygenase-2.

ST cyclooxygenase 2 inhibitor MMP13 allosteric carboxylic inhibitor
 combination therapeutic; matrix metalloproteinase 13 inhibitor
 cyclooxygenase 2 inhibitor combination therapeutic

IT Ampuls

Analgesics

Anti-inflammatory agents

Antiarthritics

Antirheumatic agents

Drug delivery systems

Inflammation

Osteoarthritis

Pain

Rheumatoid arthritis

(allosteric carboxylic inhibitor of matrix metalloproteinase-13
 combination with selective inhibitor of cyclooxygenase-2 that is not
 celecoxib or valdecoxib, and therapeutic use)

IT Drug delivery systems

(capsules; allosteric carboxylic inhibitor of matrix
 metalloproteinase-13 combination with selective inhibitor of
 cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic
 use)


IT Cartilage, disease

(damage; allosteric carboxylic inhibitor of matrix metalloproteinase-13
 combination with selective inhibitor of cyclooxygenase-2 that is not
 celecoxib or valdecoxib, and therapeutic use)


IT Drug delivery systems

(injections; allosteric carboxylic inhibitor of matrix
 metalloproteinase-13 combination with selective inhibitor of

- cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
(ointments; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
(sols.; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
(suppositories; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
(tablets, coated; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
(tablets; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT 175449-82-8, Matrix metalloproteinase 13 329900-75-6, Cyclooxygenase 2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT 449210-07-5 449210-13-3 449210-20-2
449210-24-6 449210-27-9 449210-47-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT 449210-13-3 449210-20-2 449210-24-6
449210-27-9 449210-47-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- RN 449210-13-3 HCAPLUS
- CN Pyrido[3,4-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




- RN 449210-20-2 HCAPLUS
- CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 449210-24-6 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 449210-27-9 HCAPLUS

CN Pyrido[3,4-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 449210-47-3 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)



L16 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:60302 HCAPLUS

DN 140:105333

ED Entered STN: 26 Jan 2004

TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib, pharmaceutical compositions, and therapeutic use

IN Roark, William Howard

PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl., 238 pp.

CODEN: PIXXD2

DT Patent

LA English
 IC ICM A61K031-415
 ICS A61K031-44; A61K031-42; A61K031-519
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004006912	A2	20040122	WO 2003-IB3044	20030707
	WO 2004006912	A3	20040603		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004019053	A1	20040129	US 2003-619662	20030715
PRAI	US 2002-396903P	P	20020717		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004006912	ICM	A61K031-415
	ICS	A61K031-44; A61K031-42; A61K031-519

OS MARPAT 140:105333

AB The invention provides a combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. The invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase 2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.

ST allosteric carboxylic inhibitor matrix metalloproteinase 13 celecoxib valdecoxib therapeutic; MMP13 allosteric carboxylic inhibitor celecoxib valdecoxib combination therapeutic

IT Ampuls

Analgesics

Anti-inflammatory agents

Antiarthritics

Antirheumatic agents

Drug delivery systems

Human

Inflammation

Osteoarthritis

Pain


Rheumatoid arthritis

(allosteric carboxylic inhibitor of matrix metalloproteinase-13

combination with celecoxib or valdecoxib, pharmaceutical compns.. and therapeutic use)


IT Drug delivery systems

- (capsules; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Cartilage, disease
(damage; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
(injections; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
(ointments; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Arthritis
(psoriatic arthritis; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
(solns.; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
(suppositories; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
(tablets, coated; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
(tablets; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT 175449-82-8, Matrix metalloproteinase 13
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT 169590-42-5, Celecoxib 181695-72-7, Valdecoxib 449210-07-5
449210-13-3 449210-20-2 449210-24-6
449210-27-9 449210-47-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT 449210-13-3 449210-20-2 449210-24-6
449210-27-9 449210-47-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- RN 449210-13-3 HCAPLUS
- CN Pyrido[3,4-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449210-20-2 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 449210-24-6 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 449210-27-9 HCAPLUS

CN Pyrido[3,4-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 449210-47-3 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)



=> d all fhitstr l16 3-4

L16 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:637660 HCAPLUS
 DN 137:185501
 ED Entered STN: 23 Aug 2002
 TI Preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease
 IN Andrianjara, Charles; Chantel-Barvian, Nicole; Gaudilliere, Bernard; Jacobelli, Henri; Ortwine, Daniel Fred; Patt, William Chester; Pham, Ly; Kostlan, Catherine Rose; Wilson, Michael William
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl., 264 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D239-96
 ICS C07D401-12; C07D405-12; C07D409-12; C07D405-14; C07D409-14; C07D471-04; C07D403-12; C07D403-10; C07D410-10; C07D413-10; C07D401-06; A61K031-5025; A61K031-505
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064572	A1	20020822	WO 2002-EP1979	20020211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437122	AA	20020822	CA 2002-2437122	20020211
EP 1368324	A1	20031210	EP 2002-722137	20020211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300384	A	20031215	EE 2003-384	20020211
JP 2004523546	T2	20040805	JP 2002-564505	20020211
US 2002193377	A1	20021219	US 2002-75954	20020213
NO 2003003593	A	20030813	NO 2003-3593	20030813
PRAI US 2001-268661P	P	<u>20010214</u>		
WO 2002-EP1979	W	20020211		



CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002064572	ICM	C07D239-96
	ICS	C07D401-12; C07D405-12; C07D409-12; C07D405-14; C07D409-14; C07D471-04; C07D403-12; C07D403-10; C07D410-10; C07D413-10; C07D401-06; A61K031-5025; A61K031-505
JP 2004523546	FTERM	4C063/AA01; 4C063/AA03; 4C063/BB03; 4C063/BB06; 4C063/BB08; 4C063/BB09; 4C063/CC31; 4C063/CC47; 4C063/CC58; 4C063/CC81; 4C063/CC92; 4C063/DD12; 4C063/DD28; 4C063/DD31; 4C063/EE01; 4C065/AA04; 4C065/AA05; 4C065/BB11; 4C065/CC01; 4C065/DD03; 4C065/EE02; 4C065/HH08; 4C065/JJ01; 4C065/KK01; 4C065/KK09; 4C065/LL04; 4C065/PP03; 4C065/PP07;

4C065/PP12; 4C065/QQ04; 4C065/QQ05; 4C086/AA01;
4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC46;
4C086/BC62; 4C086/BC71; 4C086/BC73; 4C086/CB09;
4C086/GA07; 4C086/GA08; 4C086/GA09; 4C086/GA12;
4C086/MA01; 4C086/MA02; 4C086/MA03; 4C086/MA04;
4C086/MA05; 4C086/NA14; 4C086/ZA15; 4C086/ZA33;
4C086/ZA36; 4C086/ZA45; 4C086/ZA67; 4C086/ZA68;
4C086/ZA96; 4C086/ZA97; 4C086/ZB15; 4C086/ZB26;
4C086/ZC20; 4C086/ZC41; 4C086/ZC52

OS CASREACT 137:185501; MARPAT 137:185501

GI



AB Title compds. I [R1 = H, amino, alkyl, alkenyl, alkynyl, alkylamino, aryl, heterocycle, etc.; W = O, S, =N-R'; R' = alkyl, OH, CN; X1-3 = N, C-R6; R6 = H, alkyl, amino, alkylamino, etc.; Y = O, S, NH, N-alkyl; Z = O, S, NR7; R7 = H, alkyl, aryl, aryl, heteroaryl, etc.; n = 1-8; Z1 = alkyl; A = (non)aromatic, 5- or 6-membered monocycle comprising from 0 to 4 heteroatoms selected from N, O, S, etc.; m = 0-7; R2 = alkyl, halo, CN, NO2, SCF3, CF3, OCF3, etc.; R3 = H, alkyl, alkenyl, alkynyl, etc.] were prepared Over 200 synthetic examples were provided. For instance, di-Me 4-aminoisophthalate was reacted with benzylisocyanate and heated to 95-100.degree. overnight to give Me 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylate which was saponified (dioxaneaq. LiOH, reflux) to give the carboxylic acid. This intermediate was coupled with benzylamine to afford II. Selected examples of I had IC50 = 2.25 - 0.001 .mu.M for MMP13 and IC50 > 100 .mu.M for MMP1, MMP2, MMP3, MMP7, MMP9, MMP12 and MMP14; II had IC50 = 0.193 .mu.M for MMP13. Compds. I are useful for the treatment of osteoarthritis and rheumatoid arthritis.

ST quinazoline mmp matrix metalloprotease inhibitor prepn

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT Lung, disease

(chronic obstructive; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT Heart, disease

(failure; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT Intestine, disease

(inflammatory; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT Eye, disease

(macula, senile degeneration; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT Antiarthritics

Antiasthmatics
 Antirheumatic agents
 Antitumor agents
 Arthritis
 Asthma
 Atherosclerosis
 Human
 Multiple sclerosis
 Neoplasm
 Osteoarthritis
 Osteoporosis
 Periodontium, disease
 Psoriasis
 Rheumatoid arthritis
 (preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT Multiple sclerosis

Osteoporosis

(therapeutic agents; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT 449208-02-0P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-pyridylmethyl)amide 449208-14-4P 449208-50-8P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-52-0P, Methyl 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449208-55-3P, 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449208-57-5P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449208-82-6P 449209-00-1P, [4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]acetic acid 449209-16-9P, Methyl 3-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-18-1P, (E)-Methyl 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]but-2-enoate 449209-20-5P, Methyl 5-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]furan-2-carboxylate 449209-22-7P, Methyl 5-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]thiophene-2-carboxylate 449209-24-9P 449209-37-4P, Methyl 2-chloro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-43-2P, Methyl 2-methoxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-44-3P, 2-Methoxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-45-4P, Methyl 2-hydroxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-47-6P, Methyl 2-methyl-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-49-8P 449209-52-3P 449209-54-5P, Methyl 4-[[6-(3-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-60-3P, 4-[[1-Methyl-6-((4-methylsulfonyl)benzyl)carbamoyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid methyl ester 449209-70-5P, 3-(4-Methoxybenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449209-75-0P, Methyl 4-[[1-methyl-2,4-dioxo-6-[[pyridin-4-yl]methyl]carbamoyl]-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-89-6P 449209-90-9P 449209-91-0P 449209-95-4P 449209-98-7P, [5-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]pyridin-2-yl]carbamic acid tert-butyl ester 449210-36-0P, 4'-[[6-((4-methoxybenzyl)carbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]biphenyl-2-carboxylic acid methyl ester 449210-88-2P, tert-Butyl 1-[4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]cyclopropanecarboxylate 449210-90-6P,

3-Benzyl-6-benzylsulfanyl-1-methyl-1H-quinazoline-2,4-dione
 449210-98-4P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid chloromethyl ester
 449210-99-5P 449211-01-2P 474663-15-5P, Ethyl 2-Fluoro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(MMP13 inhibitor; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT 449208-01-9P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-03-1P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide 449208-04-2P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (2-thienylmethyl)amide 449208-06-4P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (3-pyridylmethyl)amide 449208-07-5P 449208-08-6P 449208-09-7P 449208-10-0P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide 449208-11-1P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-12-2P, Methyl 4-[[[1-(3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)methanoyl]amino]methyl]benzoate 449208-13-3P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [4-hydroxy-3-methoxybenzyl]amide 449208-15-5P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-pyridylmethyl)amide 449208-16-6P, 1-Methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-20-2P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-22-4P, 3-(4-Methoxybenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-23-5P 449208-25-7P, 3-(1-(Naphth-1-yl)ethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-26-8P, 2,4-Dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-32-6P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-36-0P, 1-Methyl-2,4-dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-37-1P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-38-2P, 1-Methyl-2,4-dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-39-3P, 3-(4-Chlorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-40-6P, 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-41-7P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-42-8P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-46-2P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-47-3P, 3-Benzyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-48-4P, 3-Benzyl-1-cyclopropylmethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-49-5P, 3-Benzyl-1-isobutyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-56-4P, 1-Methyl-2,4-dioxo-3-((E)-3-phenylpropenyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-58-6P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449208-59-7P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-pyridylmethyl ester

449208-60-0P 449208-61-1P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [Benzo[1,3]dioxol-5-yl]methyl ester 449208-62-2P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [Benzo[1,3]dioxol-5-yl]methyl ester 449208-63-3P, 1-Benzyl-2,4-dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449208-64-4P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-Pyridylmethyl ester 449208-65-5P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-Pyridylmethyl ester 449208-66-6P, Benzyl 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylate 449208-67-7P, 3-Benzyl-6-methyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione 449208-69-9P, 4-Pyridylmethyl 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylate 449208-70-2P, 3-Benzyl-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-71-3P, 4-[[6-(4-Hydroxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449208-72-4P 449208-73-5P 449208-74-6P 449208-75-7P 449208-76-8P 449208-77-9P 449208-78-0P 449208-79-1P 449208-80-4P 449208-81-5P 449208-83-7P 449208-84-8P 449208-85-9P 449208-87-1P 449208-88-2P 449208-89-3P 449208-90-6P 449208-91-7P 449208-92-8P 449208-93-9P, Ethyl [6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]acetate 449208-94-0P 449208-95-1P, Methyl 3-[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]propionate 449208-96-2P, 3-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]propionic acid 449208-97-3P 449208-98-4P, 4-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]butyric acid 449208-99-5P, Methyl [4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]acetate 449209-01-2P 449209-02-3P 449209-04-5P 449209-06-7P 449209-07-8P 449209-09-0P 449209-13-6P 449209-14-7P 449209-17-0P, 3-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-19-2P, 4-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]but-2-enoic acid 449209-21-6P, 5-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]furan-2-carboxylic acid 449209-23-8P, 5-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]thiophene-2-carboxylic acid 449209-25-0P 449209-26-1P 449209-27-2P 449209-28-3P 449209-29-4P 449209-30-7P 449209-31-8P 449209-32-9P 449209-33-0P 449209-34-1P 449209-36-3P 449209-39-6P, 2-Chloro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-40-9P 449209-41-0P 449209-46-5P, 2-Hydroxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-48-7P, 2-Methyl-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-53-4P 449209-59-0P, 4-[[6-(3-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-61-4P, 4-[[1-Methyl-6-(4-methylsulfanylbenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-62-5P, 4-[[1-Methyl-2,4-dioxo-6-(4-(trifluoromethoxy)benzylcarbamoyl)-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid methyl ester 449209-63-6P, Methyl 4-[[6-(4-fluorobenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-64-7P, 4-[[6-(4-Fluorobenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-65-8P, Methyl 4-[[6-[(benzofurazan-5-yl)methyl]carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-66-9P, 4-[[6-[(Benzofurazan-5-yl)methyl]carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-67-0P, Methyl 4-[[6-(4-methoxybenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-68-1P, Methyl 4-[[1-ethyl-6-(4-methoxybenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-

yl)methyl]benzoate 449209-69-2P, 4-[[1-Ethyl-6-(4-methoxybenzylcarbamoyle)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoic acid 449209-71-6P, 3-(4-Hydroxybenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449209-72-7P, 3-(4-Cyanobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449209-74-9P, 1-Methyl-2,4-dioxo-3-(3-(pyridin-4-yl)propenyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449209-76-1P, 4-[[1-Methyl-2,4-dioxo-6-((pyridin-4-yl)methyl)carbamoyle)-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoic acid hydrochloride 449209-77-2P, Methyl [4-[[1-methyl-2,4-dioxo-6-((pyridin-4-yl)methyl)carbamoyle)-1,4-dihydro-2H-quinazolin-3-yl)methyl]phenyl]acetate 449209-78-3P, [4-[[1-Methyl-2,4-dioxo-6-((pyridin-4-yl)methyl)carbamoyle)-1,4-dihydro-2H-quinazolin-3-yl)methyl]phenyl]acetic acid hydrochloride 449209-79-4P 449209-80-7P 449209-81-8P, Methyl [6-[[1,3-Benzodioxol-5-yl)methyl]carbamoyle)-3-benzyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-1-yl]acetate 449209-82-9P, [6-[[1,3-Benzodioxol-5-yl)methyl]carbamoyle)-3-benzyl-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl]acetic acid 449209-83-0P, Methyl 4-[[6-[[1,3-benzodioxol-5-yl)methyl]carbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoate 449209-84-1P, 4-[[6-[[1,3-Benzodioxol-5-yl)methyl]carbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoic acid 449209-85-2P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-(sulfamoyl)benzyl)amide 449209-86-3P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [3-(pyridin-4-ylsulfanyl)propyl]amide 449209-87-4P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-morpholin-4-ylbutyl)amide 449209-88-5P 449209-92-1P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-((dimethylcarbamoyle)methoxy)benzyl)amide 449209-93-2P 449209-94-3P 449209-96-5P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-(dimethylcarbamoyle)benzyl)amide 449209-97-6P 449209-99-8P 449210-00-8P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-yl)methyl]amide 449210-01-9P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-yl)methyl]amide 449210-03-1P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-yl)methyl]amide 449210-07-5P, 4-[[6-(4-Methoxybenzylcarbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl)methyl]benzoic acid 449210-11-1P 449210-12-2P 449210-13-3P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-yl)methyl]amide 449210-20-2P, Methyl 4-[[6-(4-Methoxybenzylcarbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl)methyl]benzoate 449210-23-5P, tert-Butyl 4-[[6-(4-methoxybenzylcarbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl)methyl]benzoate 449210-24-6P, 4-[[6-(3-Methoxybenzylcarbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl)methyl]benzoic acid 449210-27-9P 449210-28-0P, 3-Benzyl-1-methyl-6-(3-phenylpropionyl)-1H-quinazoline-2,4-dione 449210-29-1P 449210-30-4P 449210-31-5P, 3-Benzyl-1-methyl-6-[2-(pyridin-4-ylsulfanyl)acetyl]-1H-quinazoline-2,4-dione 449210-32-6P 449210-33-7P 449210-34-8P 449210-37-1P, 4'-[[6-(4-Methoxybenzylcarbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]biphenyl-2-carboxylic acid 449210-39-3P, 2-Fluoro-4-[[6-(4-methoxybenzylcarbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoic acid 449210-40-6P, 2-Methoxy-4-[[6-(4-methoxybenzylcarbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoic acid 2-dimethylaminoethyl ester 449210-41-7P, 4-[[6-(4-Methoxybenzylcarbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]-2-methylbenzoic acid 2-dimethylaminoethyl ester 449210-42-8P 449210-43-9P, [4-[6-(4-Methoxybenzylcarbamoyle)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]phenyl]acetic acid 449210-45-1P, 1-Methyl-3-(1-(naphthalen-1-yl)ethyl)-2,4-dioxo-1,2,3,4-

tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide
 449210-47-3P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-
 1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoic acid
 449210-49-5P, 3-(3-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide
 449210-51-9P, 3-(3-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-
 yl)methyl)amide 449210-52-0P, 3-(3-Fluorobenzyl)-1-methyl-2,4-dioxo-
 1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-3-
 yl)methyl)amide 449210-53-1P 449210-54-2P 449210-55-3P,
 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((pyridin-4-yl)methyl)amide 449210-56-4P,
 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((pyridin-3-yl)methyl)amide 449210-57-5P 449210-61-1P,
 3-(4-Bromobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-62-2P,
 3-(3,4-Difluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid (pyridin-3-ylmethyl)amide 449210-66-6P,
 3-(3,4-Difluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid (pyridin-4-ylmethyl)amide 449210-67-7P 449210-68-8P,
 3-(3-Chloro-4-fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide
 449210-72-4P 449210-73-5P 449210-74-6P 449210-75-7P 449210-76-8P,
 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((pyridin-4-yl)methyl)amide 449210-78-0P,
 3-(4-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((pyridin-4-yl)methyl)amide 449210-79-1P,
 3-(4-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((pyridin-3-yl)methyl)amide 449210-81-5P,
 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid ((pyridin-3-yl)methyl)amide 449210-82-6P 449210-84-8P
 449210-85-9P, 3-(4-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-
 yl)methyl)amide 449210-87-1P, 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-
 1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-
 yl)methyl)amide 449210-89-3P, 1-[4-[[6-(4-Methoxybenzylcarbamoyl)-1-
 methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]cyclopropane
 carboxylic acid 449210-92-8P, 3-Benzyl-1-methyl-6-
 ((phenylmethyl)sulfinyl)-1H-quinazoline-2,4-dione 449210-93-9P,
 3-Benzyl-1-methyl-6-((phenylmethyl)sulfonyl)-1H-quinazoline-2,4-dione
 449210-94-0P 449210-95-1P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-
 dioxo-1,4-dihydro-2H-quinazoline-3-yl]methyl]benzoic acid
 3-(dimethylamino)-2,2-dimethylpropyl ester 449210-96-2P,
 4-[[6-((4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 quinazoline-3-yl]methyl]benzoic acid 2-(dimethylamino)-2-methylpropyl
 ester 449210-97-3P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-
 1,4-dihydro-2H-quinazoline-3-yl]methyl]benzoic acid 2-dimethylaminoethyl
 ester 449211-00-1P 449211-04-5P 449211-08-9P 449211-12-5P,
 4-[[6-((3-Methoxybenzylcarbamoyl)methyl)-2,4-dioxo-1,4-dihydro-2H-
 quinazolin-3-yl]methyl]benzoic acid methyl ester 449211-14-7P,
 4-[[1-Ethyl-2,4-dioxo-6-((4-(trifluoromethoxy)benzyl)carbamoyl)-1,4-
 dihydro-2H-quinazolin-3-yl]methyl]benzoic acid methyl ester
 449211-16-9P, 4-[[1-Methyl-2,4-dioxo-6-[(pyridin-4-ylmethyl)carbamoyl]-1,4-
 dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449211-18-1P,
 [4-[[1-Methyl-2,4-dioxo-6-[(pyridin-4-ylmethyl)carbamoyl]-1,4-dihydro-2H-
 quinazolin-3-yl]methyl]phenyl]acetic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(MMP13 inhibitor; preparation of quinazolines as specific inhibitors of
 type-13 matrix metalloprotease)

IT 4315-09-7P, 4-Nitroisophthalic acid 23965-06-2P, 3-Benzyl-6-bromo-1H-
 quinazoline-2,4-dione 33857-88-4P 63746-12-3P, Dimethyl
 4-aminoisophthalate 69048-70-0P, Dimethyl 4-nitroisophthalate

69209-73-0P 151979-21-4P, 5-Iodo-2-((methyl)amino)benzoic acid
 177913-48-3P, Dimethyl 4-amino-1-hydroxycyclohexa-3,5-diene-1,3-
 dicarboxylate 184681-83-2P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-
 tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 209604-61-5P,
 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl
 ester 221540-53-0P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 342644-48-8P,
 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-
 carboxylic acid ethyl ester 449207-91-4P, 3-Benzyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid 449207-92-5P 449207-93-6P,
 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carbonitrile
 449207-94-7P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid 449207-95-8P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449207-96-9P,
 1-Methyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid 449207-97-0P, 3-(3-Fluorobenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449207-98-1P,
 1-Methyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid methyl ester 449207-99-2P, 1-Ethyl-3-(3-fluorobenzyl)-
 2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-00-8P,
 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid methyl ester 449208-17-7P, 2,4-Dioxo-3-phenethyl-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-18-8P,
 2,4-Dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid
 449208-19-9P, 2,4-Dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-21-3P,
 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic
 acid 449208-24-6P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid (4-methoxybenzyl)amide
 449208-27-9P, Dimethyl 4-(N'-((pyridin-4-yl)methyl)ureido)isophthalate
 449208-29-1P, 2,4-Dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-31-5P,
 2,4-Dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid 449208-33-7P 449208-34-8P, 2,4-Dioxo-3-(thien-2-
 ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester
 449208-35-9P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-
 6-carboxylic acid 449208-43-9P 449208-44-0P, 3-((Benzo[1,3]dioxol-5-
 yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid
 methyl ester 449208-45-1P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-
 1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-51-9P,
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl
 ester 449208-53-1P 449208-68-8P, 3-Benzyl-2,4-dioxo-1,2,3,4-
 tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 449209-10-3P,
 3-(4-Chlorosulfonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-11-4P,
 3-(4-Dimethylsulfamoylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-12-5P,
 3-(4-Dimethylsulfamoylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid 449209-15-8P,
 1-Methyl-3-(4-methylsulfamoylbenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-50-1P,
 2,4-Dioxo-1-methyl-3-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid methyl ester 449209-51-2P, 2,4-Dioxo-1-methyl-3-
 (pyridine-4-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid
 449209-55-6P, 3-(4-Methoxycarbonylbenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid benzyl ester 449209-57-8P,
 3-(4-Methoxycarbonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid benzyl ester 449209-58-9P,
 3-(4-Methoxycarbonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid 449209-73-8P,
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid
 (pyridin-4-ylmethyl)amide 449210-02-0P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-
 tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid 449210-04-2P
 449210-05-3P 449210-06-4P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-

tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 449210-08-6P,
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic
 acid 449210-09-7P 449210-10-0P, Methyl 4-[[6-(4-
 Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-
 d]pyrimidin-3-yl]methyl]benzoate 449210-14-4P, 1-Benzyl-2,6-dioxo-
 1,2,3,6-tetrahydropyrimidine-4-carboxaldehyde 449210-15-5P
 449210-16-6P 449210-17-7P 449210-18-8P, 3-Benzyl-1-methyl-2,4-dioxo-
 1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid methyl ester
 449210-19-9P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-
 d]pyrimidine-6-carboxylic acid 449210-21-3P, 1-Methyl-2,4-dioxo-1,2,3,4-
 tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid 449210-22-4P
 449210-25-7P 449210-26-8P, tert-Butyl 4-[[6-(3-
 Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-
 d]pyrimidin-3-yl]methyl]benzoate 449210-58-6P, 3-(4-Bromobenzyl)-2,4-
 dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester
 449210-59-7P, 1-Methyl-3-(4-bromobenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-60-0P,
 1-Methyl-3-(4-bromobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid 449210-63-3P, 3-(3,4-Difluorobenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-64-4P,
 1-Methyl-3-(3,4-difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-
 carboxylic acid methyl ester 449210-65-5P, 1-Methyl-3-(3,4-
 difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid
 449210-69-9P, 3-(3-Chloro-4-fluorobenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-70-2P,
 1-Methyl-3-(3-chloro-4-fluorobenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-71-3P,
 1-Methyl-3-(3-chloro-4-fluorobenzyl)-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid 449210-77-9P,
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid
 (pyridazin-4-ylmethyl)amide 449210-80-4P, 1-Methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid (pyridin-3-ylmethyl)amide
 449210-83-7P 449210-86-0P, 1-Methyl-2,4-dioxo-1,2,3,4-
 tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-
 yl)methyl)amide 449210-91-7P, 3-Benzyl-6-iodo-1-methyl-1H-quinazoline-
 2,4-dione

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of quinazolines as specific inhibitors of type-13
 matrix metalloprotease)

IT 9001-12-1, MMP-1 9004-06-2, MMP-12 79955-99-0, MMP 3 141256-52-2,
 MMP 7 146480-35-5, MMP-2 146480-36-6, MMP-9 161384-17-4, MMP-14
 175449-82-8, MMP-13

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of quinazolines as specific inhibitors of type-13 matrix
 metalloprotease)

IT 78-73-9, Choline bicarbonate 78-77-3, Isobutyl bromide 79-07-2,
 2-Chloroacetamide 96-32-2, Methyl bromoacetate 96-33-3, Methyl
 acrylate 100-11-8, 4-Nitrobenzyl bromide 100-44-7, Benzyl chloride,
 reactions 100-46-9, Benzylamine, reactions 100-51-6, Benzyl alcohol,
 reactions 104-84-7, 4-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine
 105-36-2, Ethyl bromoacetate 105-39-5, Ethyl 2-chloroacetate 106-95-6,
 Allyl bromide, reactions 106-96-7, Prop-2-ynyl bromide 108-00-9,
 N,N-Dimethylethylene diamine 108-01-0, 2-(Dimethylamino)ethanol
 119-68-6, N-Methylantranilic acid 138-39-6, 4-
 (Aminomethyl)benzenesulfonamide 140-75-0, 4-Fluorobenzylamine
 140-88-5, Ethyl acrylate 332-48-9, 2-(4-Fluorophenoxy)ethyl bromide
 351-52-0, 4-Chloromethyl-2-fluoro-1-methoxybenzene 459-46-1 495-76-1,
 Piperonyl alcohol 540-51-2, 2-Bromoethanol 586-95-8, 4-Pyridylcarbinol
 593-71-5, Chloriodomethane 622-78-6, Benzyl isothiocyanate 622-95-7,
 4-Chlorobenzyl bromide 637-59-2, 3-Phenylpropyl bromide 870-63-3,
 1-Bromo-3-methylbut-2-ene 874-89-5, 4-Hydroxymethylbenzonitrile
 874-98-6, 3-(Bromomethyl)-1-methoxyphenyl 938-09-0, 2-Chloroethyl phenyl
 sulfone 1117-71-1, Methyl 4-bromocrotonate 1129-28-8, Methyl

3-(bromomethyl)benzoate 1943-82-4, Phenethyl isocyanate 2144-37-8, Methyl 5-(chloromethyl)-2-furoate 2393-23-9, 4-Methoxybenzylamine 2417-72-3, Methyl 4-(bromomethyl)benzoate 2550-36-9, (Bromomethyl)cyclohexane 2620-50-0, Piperonylamine 2969-81-5, Ethyl 4-bromobutyrate 3113-72-2, 5-Methyl-2-nitrobenzoic acid 3173-56-6, Benzyl isocyanate 3277-89-2, Phenethylmagnesium bromide 3395-91-3, Methyl 3-bromopropanoate 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1, 4-Picolylamine 4070-48-8, 4637-24-5, 5071-96-5, 3-Methoxybenzylamine 5586-89-0, 5794-88-7, 2-Amino-5-bromobenzoic acid 6232-11-7, Methyl 4-(aminomethyl)benzoate hydrochloride 6321-07-9, 4-Morpholin-4-ylbutylamine 6482-24-2, 1-Bromo-2-methoxyethane 7005-47-2, 2-(Dimethylamino)-2-methylpropanol 7051-34-5, Cyclopropylmethyl bromide 7149-10-2, 4-Hydroxy-3-methoxybenzylamine hydrochloride 7398-42-7, Methyl 4-(bromomethyl)phenylacetate 10406-25-4, 13734-41-3, 17201-43-3, 4-(Bromomethyl)benzonitrile 18469-52-8, Methyl 4-aminomethyl benzoate 19059-68-8, 3-(Dimethylamino)-2,2-dimethylpropanol 22059-22-9, N-Hydroxyacetamide 22600-30-2, Methyl 5-amino-2-furan carboxylate 25589-18-8, 3-Benzyl-6-methyl-1H-pyrimidine-2,4-dione 26146-77-0, (E)-Cinnamyl bromide 27757-85-3, 2-Thienylmethylamine 28188-41-2, 3-(Bromomethyl)benzonitrile 30260-66-3, Dimethylhydrazine 30280-44-5, 4-Chlorobenzyl isocyanate 32863-31-3, 5-Bromomethylbenzofurazan 39077-96-8, 40724-47-8, 4-Bromomethylbenzenesulfonamide 41886-04-8, 3-Bromomethyl-1-methylpiperidine 50541-93-0, 4-Amino-1-benzylpiperidine 55401-97-3, 2-(Bromomethyl)pyridine 56651-60-6, 4-Methoxybenzyl isocyanate 69966-55-8, 3-(Bromomethyl)pyridine 72235-53-1, 3,4-Difluorobenzylamine 72235-56-4, 3-Chloro-4-fluorobenzylamine 74733-27-0, Methyl 4-bromomethyl-2-methoxybenzoate 74733-28-1, Methyl 4-bromomethyl-2-methyl benzoate 78358-86-8, 1-(2-Bromoethyl)pyrrole 78826-46-7, (tert-Butoxy)acetyl chloride 83171-39-5, 4-Methylthiobenzylamine 85070-57-1, Methyl 4-(bromomethyl)-2-fluorobenzoate 85147-14-4, 88442-63-1, 1-(1-Naphthyl)ethyl isocyanate 89583-07-3, 4-(2-Bromoethyl)morpholine 93919-56-3, 4-Trifluoromethoxybenzylamine 99067-96-6, (4-(Dimethylamino)benzyl)isocyanate 102422-56-0, 3-Fluorobenzyl isocyanate 108052-76-2, tert-Butyl 4-bromomethylbenzoate 108499-32-7, Methyl 5-bromomethylthiophene-2-carboxylate 114772-38-2, 114772-54-2, 2-(4-Bromomethylphenyl)benzonitrile 120788-70-7, Ethyl 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylate 128674-45-3, 4-(3-Chloropropenyl)pyridine hydrochloride 138402-33-2, 138895-24-6, 6-Amino-3-benzyl-1H-pyrimidine-2,4-dione 148900-69-0, 154470-79-8, Methyl 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylate 155965-45-0, 220875-89-8, 5-(4-Chloromethylphenyl)-1-methyl-1H-tetrazole 221031-44-3, 2-Chloro-1-(4-diethylaminophenyl)ethan-1-one 302912-23-8, 4-Bromobenzyl isocyanate 304873-96-9, tert-Butyl (5-bromomethylpyridin-2-yl)carbamate 448965-87-5, tert-Butyl 1-(4-bromomethylphenyl)cyclopropanecarboxylate 449208-54-2, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-03-4, 3-((E)-3-Chloropropenyl)pyridine 449209-05-6, 4-((E)-3-Chloropropenyl)pyridine 449209-08-9, 3-(4-(Methanesulfonyl)benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-35-2, 3-(4-Chloromethylphenyl)-5-methyl[1,2,4]oxadiazole 449209-38-5, Methyl 2-chloro-4-chloromethylbenzoate 449209-42-1, 5-(4-Chloromethylphenyl)-2-methyl-2H-tetrazole 449209-56-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant: preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Abou-Hadeed, K; PTERIDINES 1996, V7(4), P113 HCAPLUS


(2) Anon; AMBINTER: EXPLORATORY LIBRARY 2002

(3) Anon; CHEMSTAR PRODUCT LIST 2001

(4) Anon; SCIENTIFIC EXCHANGE PRODUCT LIST 2001

(5) Anon; SCREENING COLLECTION 2000

- (6) Bemis, G; WO 9964400 A 1999 HCAPLUS
 (7) Brittelli, D; WO 9743239 A 1997 HCAPLUS
 (8) Chen, J; JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 2000, V122, P9648 HCAPLUS
 (9) Ciba Geigy Ag; DE 2441959 A 1975 HCAPLUS
 (10) Ghose, A; J MED CHEM 1984, V27(7), P901 HCAPLUS
 (11) Kim, Y; CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997. PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON PTERIDINES AND FOLATES, 11TH 1997, P41 MEDLINE
 (12) Lespagnol, A; BULL SOC PHARM LILLE 1977, V33(1), P67 HCAPLUS
 (13) Liverton, N; BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1998, V8(5), P483 HCAPLUS
 (14) Murata, S; CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997. PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON PTERIDINES AND FOLATES, 11TH 1997, P17 HCAPLUS
 (15) Nesterov; SU 119879 A 1959 HCAPLUS
 (16) Ogawa, H; CHEM PHARM BULL 1988, V36(6), P2253 HCAPLUS
 (17) Reiter, L; BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1999, V9(2), P127 HCAPLUS
 (18) Sladowska, H; FARMACO, ED SCI 1986, V41(12), P954 HCAPLUS
 IT 449210-13-3P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (MMP13 inhibitor; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
 RN 449210-13-3 HCAPLUS
 CN Pyrido[3,4-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



L16 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:637472 HCAPLUS
 DN 137:201321
 ED Entered STN: 23 Aug 2002
 TI Preparation of substituted isophthalic acid derivatives, multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors
 IN Andrianjara, Charles; Ortwine, Daniel Fred; Pavlovsky, Alexander Gregory; Roark, William Howard
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl.. 173 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064080	A2	20020822	WO 2002-IB447	20020213
	WO 2002064080	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2437643 AA 20020822 CA 2002-2437643 20020213
 US 2003078276 A1 20030424 US 2002-75069 20020213
 EP 1361873 A2 20031119 EP 2002-710275 20020213

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR


BR 2002007864 A 20040309 BR 2002-7864 20020213
 JP 2004529874 T2 20040930 JP 2002-563877 20020213
 US 2005004126 A1 20050106 US 2004-835619 20040429

PRAI US 2001-268821P P 20010214
 US 2002-75069 B3 20020213
 WO 2002-1B447 W 20020213

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002064080	ICM	A61K
JP 2004529874	FTERM	4C022/CA02; 4C036/AD05; 4C036/AD12; 4C036/AD19; 4C036/AD27; 4C036/AD30; 4C050/AA01; 4C050/AA07; 4C050/BB06; 4C050/CC08; 4C050/EE04; 4C050/FF03; 4C050/GG03; 4C050/HH02; 4C055/AA01; 4C055/BB01; 4C055/CA01; 4C055/DA06; 4C055/DA17; 4C055/DB04; 4C055/DB08; 4C055/EA01; 4C063/AA01; 4C063/AA03; 4C063/BB08; 4C063/BB09; 4C063/CC31; 4C063/CC81; 4C063/CC92; 4C063/DD12; 4C063/DD31; 4C063/EE01; 4C065/AA04; 4C065/BB11; 4C065/CC01; 4C065/DD03; 4C065/EE03; 4C065/HH08; 4C065/JJ01; 4C065/LL04; 4C065/PP18; 4C071/AA01; 4C071/BB01; 4C071/CC21; 4C071/EE13; 4C071/FF05; 4C071/GG02; 4C071/HH08; 4C071/HH28; 4C071/JJ01; 4C071/LL01; 4C072/AA01; 4C072/BB02; 4C072/CC02; 4C072/CC16; 4C072/EE12; 4C072/FF09; 4C072/GG07; 4C072/GG09; 4C072/HH02; 4C072/UU01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BA13; 4C086/BC17; 4C086/BC46; 4C086/BC87; 4C086/CB05; 4C086/CB09; 4C086/CB26; 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA10; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA02; 4C086/ZA36; 4C086/ZA45; 4C086/ZA59; 4C086/ZA67; 4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB11; 4C086/ZB15; 4C086/ZB26; 4H006/AA01; 4H006/AA03; 4H006/AB20; 4H006/AB22; 4H006/AB23; 4H006/AB25; 4H006/AB27; 4H006/AB28; 4H006/BJ50; 4H006/BM30; 4H006/BM71; 4H006/BM72; 4H006/BP30; 4H006/BR30; 4H006/BT32; 4H006/BU26; 4H006/BV72; 4H006/KC30
US 2005004126	ECLA	A61K031/00; C07D213/30D2; C07D213/40B; C07D239/96; C07D285/14D; C07D285/24; C07D317/54; C07D317/58; C07D401/06+239+211; C07D401/06+239+213; C07D401/12+239+213; C07D405/12+317+213; C07D405/12+317+239; C07D405/14+317+239+213; C07D405/14+317+317+239; C07D409/06+333B+239; C07D409/12+333B+239; C07D409/14+333B+239+213; C07D409/14+333B+317+239; C07D471/04+239B+221B; C07D487/04+235C+239C; C07D487/04+249C+239C; C07D495/04+333B+239B; C07D513/04+277C+239C

GI



- AB Title compds.. I [R1 and R2 together may form a substituted aromatic ring or a heterocyclic ring; or R2 and R3 together may form substituted heterocycle; or R1, R3, or R4 = alkyl, arylalkyl, etc.; X = C, S; Y = O, N with provision when Y = N it forms a 5-membered heterocycle with R3] and II [R5, R6 = arylalkylamine, heterocyclalkoxy, etc.; R7 = H, MeO, NO2, etc.], are prepared and disclosed as matrix metalloproteinase (MMP) inhibitors. Thus, III was prepared in five steps via cyclocondensation of diethylmalonate and benzylurea with subsequent chlorination, substitution with hydrosulfide hydrate to form an in situ intermediate that was reacted with bromoacetaldehyde dimethylacetal, followed by acid catalyzed cyclization and substitution with benzylchloroformate. III was demonstrated to inhibit MMP13 with an IC50 value (in .mu.M) of 0.0230. I and II bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond resp. with Thr245, Thr247 and Met 253, the first hydrophobic group locates within the S1' channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compds. specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.
- ST pyrimidinedione prepn matrix metalloproteinase inhibitor; isophthalic carboxylate prepn matrix metalloproteinase inhibitor; metalloproteinase inhibitor pyrimidinedione antiinflammatory
- IT Antiarteriosclerotics
(antiatherosclerotics; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Lung, disease
(chronic obstructive; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Heart, disease
(failure; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Intestine, disease
(inflammatory; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Combinatorial library
(isophthalic acid derivs.; combinatorial preparation and pharmaceutical

- activity of substituted isophthalic acid derivs. as matrix metalloproteinase inhibitors)
- IT Eye, disease
(macula, senile degeneration; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antirheumatic agents
Antitumor agents
Arthritis
Asthma
Atherosclerosis
Cardiovascular agents
Human
Multiple sclerosis
Neoplasm
Osteoarthritis
Osteoporosis
Periodontium, disease
Psoriasis
Rheumatoid arthritis
(preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Multiple sclerosis
Osteoporosis
(therapeutic agents; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT 449790-74-3P 449790-84-5P 449790-90-3P 449791-35-9P
RL: CPN (Combinatorial preparation): PAC (Pharmacological activity): THU (Therapeutic use): BIOL (Biological study): CMBI (Combinatorial study): PREP (Preparation): USES (Uses)
(combinatorial preparation and pharmaceutical activity of substituted isophthalic acid derivs. as matrix metalloproteinase inhibitors)
- IT 1459-93-4P, Dimethyl isophthalate 4315-09-7P, 4-Nitroisophthalic acid 5759-76-2P 13756-42-8P, 4-Methylbenzoic acid tert-butyl ester 63746-12-3P, Dimethyl 4-aminoisophthalate 69048-70-0P, Dimethyl 4-nitroisophthalate 91360-95-1P 108052-76-2P, tert-Butyl-4-(bromomethyl)benzoate 175143-75-6P 177913-48-3P, Dimethyl 4-amino-1-hydroxycyclohexa-3,5-diene-1,3-dicarboxylate 209604-61-5P 221540-53-0P 342644-48-8P 448964-68-9P 448964-69-0P 448964-70-3P 449207-91-4P 449207-94-7P 449207-95-8P 449208-21-3P 449208-24-6P 449208-33-7P 449208-34-8P 449208-35-9P 449208-43-9P 449208-44-0P 449208-45-1P 449208-51-9P 449208-53-1P 449210-05-3P 449210-06-4P 449210-08-6P 449210-09-7P 449210-10-0P 449210-14-4P, 1-Benzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxaldehyde 449210-15-5P 449210-16-6P 449210-17-7P 449210-18-8P 449210-19-9P 449210-21-3P 449210-22-4P 449211-37-4P 449211-38-5P 449755-90-2P 449755-91-3P 449755-92-4P 449755-95-7P 449755-96-8P 449798-65-6P 449798-67-8P, 6-Benzylthiazolo[3,2-c]pyrimidine-5,7-dione 449798-69-0P 449798-70-3P 449798-72-5P 449798-74-7P 449799-51-3P 449799-52-4P 449799-63-7P 449799-64-8P 451471-59-3P 451471-60-6P 451471-61-7P 451471-62-8P 451471-63-9P 451471-64-0P 451471-65-1P 451471-66-2P 451471-67-3P 451471-68-4P 451471-69-5P 451471-70-8P 451471-71-9P 451471-72-0P 451471-73-1P 451471-74-2P 451471-75-3P
RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent)
(intermediate; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT 9001-12-1, Matrix metalloproteinase-1 79955-99-0, Matrix

metalloproteinase-3 141256-52-2. Matrix metalloproteinase-7
146480-35-5. Matrix metalloproteinase-2 146480-36-6. Matrix
metalloproteinase-9 161384-17-4. Matrix metalloproteinase-14
175449-82-8. Collagenase 3

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)

IT 149277-46-3. GenBank A0000434

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)

IT 100-46-9. Benzyl amine, reactions 104-86-9. 4-Chlorobenzyl amine
2393-23-9. 4-Methoxybenzylamine 2620-50-0. Piperonyl amine

RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial
study); RACT (Reactant or reagent)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)

IT 449792-10-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)

IT 96-33-3. Methyl acrylate 99-63-8. 1,3-Benzenedicarbonyl dichloride
100-11-8. 4-Nitrobenzylbromide 100-51-6. Benzyl alcohol, reactions
105-53-3. Diethylmalonate 108-90-7. Chlorobenzene, reactions 140-88-5.
Ethyl acrylate 459-46-1. 4-Fluorobenzyl bromide 495-76-1. Piperonyl
alcohol 501-53-1. Benzylchloroformate 538-32-9. Benzylurea 586-95-8.
4-Pyridinemethanol 609-08-5. Diethylmethyl malonate 623-51-8.
Mercapto-acetic acid, ethyl ester 874-60-2. 4-Methylbenzoyl chloride
1189-71-5. N-Chlorosulfonyl isocyanate 2206-43-1. 4-Methoxy-1,3-
benzenedicarboxylic acid 2417-72-3. Methyl-4-(bromomethyl)benzoate
3113-72-2. 5-Methyl-2-nitrobenzoic acid 3173-56-6. Benzylisocyanate
3731-53-1. Pyridin-4-ylmethylamine 4392-24-9. Cinnamyl bromide
4637-24-5 5326-47-6. 2-Amino-5-iodobenzoic acid 6232-11-7. Methyl
4-(aminomethyl)benzoate, hydrochloride 6959-47-3. Picolyl chloride,
hydrochloride 7149-10-2. 4-Hydroxy-3-methoxybenzylamine, hydrochloride
7252-83-7. Bromoacetaldehyde dimethylacetal 10147-11-2.
3-Phenyl-1-propyne 13235-60-4 13540-76-6. 3-(4-Methoxyphenyl)prop-1-
yne 17201-43-3. 4-(Bromomethyl)benzonitrile 18358-63-9.
Methyl-4-methylaminobenzoate 18469-52-8. Methyl 4-(aminomethyl)benzoate
22600-30-2. Methyl-5-amino-2-furoate 25589-18-8. 3-Benzyl-6-methyl-1H-
pyrimidine-2,4-dione 27757-85-3. 2-Thiophene methylamine 30280-44-5.
4-Chlorobenzyl isocyanate 40517-43-9. 4-Methylsulfonylbenzyl chloride
54751-01-8. 4-Bromomethylpyridine 56651-60-6. 4-Methoxybenzyl isocyanate
138895-24-6. 6-Amino-3-benzyl-1H-pyrimidine-2,4-dione 183741-86-8
305804-90-4 305805-20-3 449208-54-2 449211-43-2 449798-87-2
449799-49-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)

IT 449790-79-8P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(target compound; combinatorial preparation and pharmaceutical activity of
substituted isophthalic acid derivs. as matrix metalloproteinase
inhibitors)

IT	448964-75-8P	449208-01-9P	449208-02-0P	449208-37-1P	449208-39-3P
	449208-42-8P	449208-50-8P	449208-57-5P	449211-17-0P	
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(target compound; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)				
IT	16034-14-3P	143569-91-9P	151107-61-8P	152699-63-3P	167993-08-0P
	349396-68-5P	383163-58-4P	448964-76-9P	448964-82-7P	448964-84-9P
	448964-85-0P	448964-86-1P	448964-90-7P	448964-94-1P	448964-98-5P
	448964-99-6P	448965-31-9P	448965-33-1P	448965-35-3P	448965-36-4P
	448965-38-6P	448965-39-7P	448965-41-1P	448965-42-2P	448965-43-3P
	448965-44-4P	448965-46-6P	448965-47-7P	448965-48-8P	448965-49-9P
	448965-50-2P	448965-51-3P	448965-57-9P	448965-58-0P	448965-59-1P
	448965-60-4P	448965-64-8P	448965-66-0P	448965-67-1P	448965-69-3P
	448965-70-6P	448965-71-7P	448965-72-8P	448965-73-9P	448965-74-0P
	448965-75-1P	448965-76-2P	448965-77-3P	448965-78-4P	448965-79-5P
	448965-80-8P	448965-82-0P	448965-89-7P	448965-91-1P	448965-93-3P
	448965-96-6P	448965-97-7P	448965-98-8P	448965-99-9P	448966-00-5P
	448966-01-6P	448966-02-7P	448966-03-8P	448966-04-9P	448966-05-0P
	448966-06-1P	448966-07-2P	448966-09-4P	448966-10-7P	448966-11-8P
	448966-12-9P	448966-13-0P	448966-14-1P	448966-15-2P	448966-16-3P
	448966-17-4P	448966-19-6P	448966-21-0P	448966-22-1P	448966-23-2P
	448966-24-3P	448966-25-4P	448966-26-5P	448966-27-6P	448966-28-7P
	448966-29-8P	448966-30-1P	448966-31-2P	448966-32-3P	448966-33-4P
	448966-34-5P	448966-35-6P	448966-36-7P	448966-42-5P	448966-45-8P
	448966-50-5P	448966-52-7P	448966-53-8P	448966-57-2P	448966-65-2P
	448966-68-5P	448966-71-0P	448966-72-1P	448966-75-4P	448966-77-6P
	448966-78-7P	448966-85-6P	448966-86-7P	448966-87-8P	448966-88-9P
	448966-92-5P	448966-94-7P	448966-95-8P	448966-96-9P	448966-97-0P
	448967-02-0P	448967-05-3P	448967-06-4P	448967-07-5P	448967-08-6P
	448967-09-7P	448967-10-0P	448967-12-2P	448967-13-3P	448967-14-4P
	448967-16-6P	448967-19-9P	448967-20-2P	448967-21-3P	448967-23-5P
	448967-24-6P	448967-25-7P	448967-26-8P	448967-27-9P	448967-28-0P
	448967-29-1P	448967-30-4P	448967-31-5P	448967-34-8P	448967-35-9P
	448967-38-2P	448967-39-3P	448967-41-7P	448967-44-0P	448967-45-1P
	448967-47-3P	448967-48-4P	448967-49-5P	448967-50-8P	448967-52-0P
	448967-53-1P	448967-54-2P	448967-56-4P	448967-57-5P	448967-59-7P
	448967-60-0P	448967-61-1P	448967-63-3P	448967-64-4P	448967-66-6P
	448967-69-9P	448967-71-3P	448967-72-4P	448967-73-5P	448967-74-6P
	448967-76-8P	448967-80-4P	448967-81-5P	448967-82-6P	448967-87-1P
	448967-88-2P	448967-92-8P	448967-93-9P	448967-94-0P	448967-96-2P
	448967-97-3P	448967-98-4P	448967-99-5P	448968-00-1P	448968-03-4P
	448968-11-4P	448968-12-5P	448968-16-9P	448968-19-2P	448968-23-8P
	448968-24-9P	448968-27-2P	448968-28-3P	448968-30-7P	448968-34-1P
	448968-35-2P	448968-40-9P	448968-41-0P	448968-43-2P	448968-44-3P
	448968-45-4P	448968-49-8P	448968-51-2P	448968-53-4P	448968-54-5P
	448968-55-6P	448968-68-1P	448968-69-2P	448970-24-9P	449208-03-1P
	449208-04-2P	449208-06-4P	449208-07-5P	449208-08-6P	449208-09-7P
	449208-10-0P	449208-11-1P	449208-12-2P	449208-13-3P	449208-14-4P
	449208-15-5P	449208-16-6P	449208-20-2P	449208-22-4P	449208-23-5P
	449208-26-8P	449208-32-6P	449208-36-0P	449208-38-2P	449208-40-6P
	449208-41-7P	449208-46-2P	449208-47-3P	449208-48-4P	449208-49-5P
	449208-52-0P	449208-55-3P	449208-58-6P	449208-59-7P	449208-60-0P
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(target compound; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)				
IT	449208-61-1P	449208-62-2P	449208-63-3P	449208-64-4P	449208-65-5P
	449208-66-6P	449208-69-9P	449208-70-2P	449208-71-3P	449208-72-4P
	449208-73-5P	449208-74-6P	449208-75-7P	449208-76-8P	449208-77-9P

449208-78-0P	449208-79-1P	449208-80-4P	449208-81-5P	449208-82-6P
449208-83-7P	449208-84-8P	449208-85-9P	449208-87-1P	449208-88-2P
449208-89-3P	449208-90-6P	449208-91-7P	449208-92-8P	449208-93-9P
449208-94-0P	449208-95-1P	449208-96-2P	449208-97-3P	449208-98-4P
449208-99-5P	449209-00-1P	449209-01-2P	449209-06-7P	449209-07-8P
449209-09-0P	449209-13-6P	449209-14-7P	449209-16-9P	449209-17-0P
449209-18-1P	449209-19-2P	449209-20-5P	449209-21-6P	449209-22-7P
449209-23-8P	449209-24-9P	449209-25-0P	449209-26-1P	449209-27-2P
449209-28-3P	449209-29-4P	449209-30-7P	449209-31-8P	449209-32-9P
449209-33-0P	449209-34-1P	449209-36-3P	449209-37-4P	449209-39-6P
449209-40-9P	449209-41-0P	449209-43-2P	449209-44-3P	449209-45-4P
449209-46-5P	449209-47-6P	449209-48-7P	449209-49-8P	449209-52-3P
449209-53-4P	449209-54-5P	449209-59-0P	449209-60-3P	449209-61-4P
449209-63-6P	449209-64-7P	449209-65-8P	449209-66-9P	449209-67-0P
449209-68-1P	449209-69-2P	449209-70-5P	449209-71-6P	449209-72-7P
449209-75-0P	449209-77-2P	449209-79-4P	449209-81-8P	449209-82-9P
449209-83-0P	449209-84-1P	449209-86-3P	449209-89-6P	449209-90-9P
449209-91-0P	449209-94-3P	449209-97-6P	449209-98-7P	449209-99-8P
449210-00-8P	449210-01-9P	449210-03-1P	449210-07-5P	449210-11-1P

449210-12-2P 449210-13-3P 449210-20-2P

449210-24-6P	449210-27-9P	449210-28-0P	449210-29-1P	
449210-30-4P	449210-31-5P	449210-32-6P	449210-33-7P	449210-34-8P
449210-36-0P	449210-37-1P	449210-38-2P	449210-39-3P	449210-40-6P
449210-41-7P	449210-42-8P	449210-45-1P	449210-47-3P	
449210-49-5P	449210-51-9P	449210-52-0P	449210-53-1P	449210-54-2P
449210-55-3P	449210-56-4P	449210-57-5P	449210-61-1P	449210-62-2P
449210-66-6P	449210-67-7P	449210-68-8P	449210-72-4P	449210-74-6P
449210-75-7P	449210-76-8P	449210-78-0P	449210-79-1P	449210-81-5P
449210-82-6P	449210-84-8P	449210-85-9P	449210-87-1P	449210-88-2P
449210-89-3P	449210-90-6P	449210-95-1P	449210-96-2P	449210-97-3P
449211-02-3P	449211-03-4P	449211-04-5P	449211-05-6P	449211-06-7P
449211-07-8P	449211-08-9P	449211-09-0P	449211-10-3P	449211-11-4P
449211-13-6P	449211-14-7P	449211-15-8P	449211-16-9P	449211-18-1P
449211-19-2P	449211-20-5P	449211-21-6P	449211-22-7P	449211-24-9P
449211-25-0P	449211-27-2P	449211-28-3P	449211-29-4P	449211-30-7P
449211-31-8P	449211-32-9P	449211-33-0P	449211-34-1P	449211-35-2P
449211-36-3P	449754-49-8P	449754-50-1P	449754-51-2P	449754-53-4P
449754-59-0P	449754-61-4P	449754-62-5P	449754-64-7P	449754-65-8P
449754-66-9P	449754-67-0P	449754-69-2P	449754-70-5P	449754-72-7P
449754-73-8P	449754-74-9P	449754-75-0P	449754-76-1P	449754-77-2P
449754-78-3P	449754-79-4P	449754-80-7P	449754-82-9P	449754-83-0P
449754-84-1P	449754-85-2P	449754-86-3P	449754-87-4P	449754-88-5P
449754-89-6P	449754-97-6P	449754-99-8P	449790-17-4P	449790-22-1P
449790-25-4P	449790-28-7P	449790-33-4P	449790-36-7P	449790-39-0P
449790-42-5P	449790-45-8P	449790-52-7P	449790-57-2P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(target compound; preparation and pharmaceutical activity of substituted
isophthalic acid derivs., multicyclic pyrimidinediones and analogs
thereof as matrix metalloproteinase inhibitors)

IT	449790-60-7P	449790-66-3P	449790-70-9P	449790-87-8P	449790-95-8P
	449790-98-1P	449791-01-9P	449791-04-2P	449791-09-7P	449791-12-2P
	449791-15-5P	449791-18-8P	449791-20-2P	449791-28-0P	449791-31-5P
	449791-41-7P	449791-44-0P	449791-47-3P	449791-50-8P	449791-53-1P
	449791-56-4P	449791-59-7P	449791-62-2P	449791-65-5P	449791-68-8P
	449791-71-3P	449791-74-6P	449791-77-9P	449791-81-5P	449791-84-8P
	449791-90-6P	449791-93-9P	449791-96-2P	449791-99-5P	449792-02-3P
	449792-04-5P	449792-07-8P	449792-13-6P	449798-64-5P	449798-68-9P
	449798-71-4P	449798-75-8P	449798-80-5P	449798-81-6P	449798-82-7P
	449798-86-1P	449798-88-3P	449798-90-7P	449798-91-8P	449798-94-1P
	449798-95-2P	449798-97-4P	449799-02-4P	449799-05-7P	449799-06-8P
	449799-14-8P	449799-16-0P	449799-19-3P	449799-27-3P	449799-34-2P
	449799-36-4P	449799-37-5P	449799-38-6P	449799-40-0P	449799-42-2P

449799-43-3P 449799-44-4P 449799-45-5P 449799-50-2P 449799-53-5P
 449799-55-7P 449799-58-0P 449799-59-1P 449799-60-4P 449799-62-6P
 449799-65-9P 449799-66-0P 449799-67-1P 449799-70-6P 449799-71-7P
 449799-72-8P 449799-73-9P 449799-74-0P 449799-76-2P 449799-77-3P
 449799-78-4P 449799-79-5P 449799-80-8P 449799-81-9P 449799-84-2P
 449799-85-3P 449799-86-4P 449799-87-5P 449799-89-7P 449799-90-0P
 449799-93-3P 449799-96-6P 449799-97-7P 449799-98-8P 449800-01-5P
 449800-03-7P 449800-04-8P 449800-05-9P 449800-07-1P 449800-08-2P
 449800-09-3P 449800-12-8P 449800-13-9P 449800-15-1P 449800-19-5P
 451471-31-1P 451471-32-2P 451471-33-3P 451471-34-4P 451471-35-5P
 451471-36-6P 451471-37-7P 451471-38-8P 451471-39-9P,
 Thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester 451471-40-2P
 451471-41-3P 451471-42-4P 451471-43-5P 451471-44-6P 451471-45-7P
 451471-47-9P 451471-48-0P 451471-49-1P 451471-50-4P 451471-51-5P
 451471-52-6P 451471-53-7P 451471-54-8P 451471-55-9P 451471-56-0P
 451471-57-1P 451471-58-2P 451473-18-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(target compound; preparation and pharmaceutical activity of substituted
 isophthalic acid derivs., multicyclic pyrimidinediones and analogs
 thereof as matrix metalloproteinase inhibitors)

IT 452379-12-3

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(unclaimed protein sequence; preparation and pharmaceutical activity of
 substituted isophthalic acid derivs., multicyclic pyrimidinediones and
 analogs thereof as matrix metalloproteinase inhibitors)


IT 449210-13-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(target compound; preparation and pharmaceutical activity of substituted
 isophthalic acid derivs., multicyclic pyrimidinediones and analogs
 thereof as matrix metalloproteinase inhibitors)

RN 449210-13-3 HCAPLUS


CN Pyrido[3,4-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-
 1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-3-(phenylmethyl)- (9CI) (CA INDEX
 NAME)




=> b home

FILE 'HOME' ENTERED AT 11:48:16 ON 07 FEB 2005


=>





$C_{26}H_{24}N_4O_6$



$C_{25}H_{22}N_4O_6$



$C_{25}H_{22}N_4O_6$



=> b reg

FILE 'REGISTRY' ENTERED AT 13:41:49 ON 07 FEB 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7
 DICTIONARY FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide 125 tot

L25 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN

RN 449210-47-3 REGISTRY

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-
 1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA
 INDEX NAME)

OTHER NAMES:

CN 4-[[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-
 pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoic acid

FS 3D CONCORD


MF C25 H22 N4 O6

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
 (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L25 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN


RN 449210-27-9 REGISTRY

CN Pyrido[3,4-d]pyrimidine-6-carboxamide, 3-[[[(4-cyanophenyl)methyl]-1,2,3,4-
 tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA
 INDEX NAME)

FS 3D CONCORD

MF C25 H21 N5 O4

SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
 DT.CA CAplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L25 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 449210-24-6 REGISTRY
 CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-[[[6-(3-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoic acid

FS 3D CONCORD


MF C25 H22 N4 O6

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L25 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 449210-20-2 REGISTRY
 CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Methyl 4-[[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoate

FS 3D CONCORD


MF C26 H24 N4 O6

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L25 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN

RN 449210-11-1 REGISTRY

CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C25 H21 N5 O4

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L25 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN

RN 449210-10-0 REGISTRY

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Methyl 4-[[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoate

FS 3D CONCORD


MF C26 H24 N4 O6

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L25 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN

RN **449210-07-5** REGISTRY

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-[[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoic acid

FS 3D CONCORD


MF C25 H22 N4 O6

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 11:20:28 ON 07 FEB 2005)

FILE 'HCAPLUS' ENTERED AT 11:20:35 ON 07 FEB 2005

L1 1 US20020193377/PN
E US2001-268661/AP,PRN
L2 1 US2001-268661P/AP,PRN
L3 1 L1-2

FILE 'REGISTRY' ENTERED AT 11:21:44 ON 07 FEB 2005

FILE 'HCAPLUS' ENTERED AT 11:21:46 ON 07 FEB 2005
L4 TRA L3 1- RN : 441 TERMS

FILE 'REGISTRY' ENTERED AT 11:21:48 ON 07 FEB 2005
L5 441 SEA L4

FILE 'WPIX' ENTERED AT 11:21:54 ON 07 FEB 2005
L6 1 US20020193377/PN
L7 1 US2001-268661P/AP,PRN
E US2001-268661/AP,PRN
L8 1 L6-7

FILE 'HCAPLUS' ENTERED AT 11:22:40 ON 07 FEB 2005

FILE 'WPIX' ENTERED AT 11:22:53 ON 07 FEB 2005

FILE 'HOME' ENTERED AT 11:23:05 ON 07 FEB 2005

FILE 'STNGUIDE' ENTERED AT 11:23:25 ON 07 FEB 2005

FILE 'REGISTRY' ENTERED AT 11:35:05 ON 07 FEB 2005
L9 STR
L10 0 L9
L11 STR L9
L12 0 L11
L13 STR L11
L14 0 L13
L15 7 L13 FULL
SAV TEM L15 TRU954F0/A

FILE 'HCAPLUS' ENTERED AT 11:45:42 ON 07 FEB 2005
L16 4 L15

FILE 'HCAOLD' ENTERED AT 11:45:49 ON 07 FEB 2005
L17 0 L15

FILE 'REGISTRY' ENTERED AT 12:38:36 ON 07 FEB 2005
L18 168 L5 AND METHOXY
L19 147 L18 AND 2(1A) 4 (1A) DIOXO

FILE 'STNGUIDE' ENTERED AT 12:45:00 ON 07 FEB 2005

FILE 'REGISTRY' ENTERED AT 13:05:15 ON 07 FEB 2005
L20 53 BENZYL CARBAMOYL AND L5
L21 4 L5 AND 3(1A) 4(1A) CYANO

FILE 'STNGUIDE' ENTERED AT 13:15:47 ON 07 FEB 2005

FILE 'REGISTRY' ENTERED AT 13:38:03 ON 07 FEB 2005
L22 626 C26H24N4O6 OR C25H22N4O6 OR C25H22N4O6 OR C25H21N5O4
L23 315 L22 AND NR=4
L24 9 NCNC3-NC5/ES AND L23
SEL RN 2-8
L25 7 E1-7 AND L24

FILE 'HCAPLUS' ENTERED AT 13:43:10 ON 07 FEB 2005
L26 4 L25

=> b hcap

FILE 'HCAPLUS' ENTERED AT 13:43:39 ON 07 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 6 Feb 2005 (20050206/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d all hitstr 126 tot

L26 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:60320 HCAPLUS

DN 140:105336

ED Entered STN: 26 Jan 2004

TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use

IN Roark, William Howard

PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl., 239 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-519

ICS A61K031-00; A61P019-02; A61P009-00

CC 1-12 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004006931	A2	20040122	WO 2003-IB3098	20030707
	WO 2004006931	A3	20040513		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004019054	A1	20040129	US 2003-619769	20030715
---------------	----	----------	----------------	----------

PRAI US 2002-396785P	P	20020717
----------------------	---	----------

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004006931	ICM	A61K031-519
	ICS	A61K031-00; A61P019-02; A61P009-00

OS MARPAT 140:105336

AB The invention provides a combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib, and their use for the treatment of diseases that are responsive to inhibition of MMP-13 and cyclooxygenase-2.

ST cyclooxygenase 2 inhibitor MMP13 allosteric carboxylic inhibitor combination therapeutic; matrix metalloproteinase 13 inhibitor cyclooxygenase 2 inhibitor combination therapeutic

IT Ampuls

Analgesics
 Anti-inflammatory agents
 Antiarthritics
 Antirheumatic agents
 Drug delivery systems
 Inflammation
 Osteoarthritis
 Pain
 Rheumatoid arthritis


(allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)

- IT Drug delivery systems
 (capsules; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Cartilage, disease
 (damage; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
 (injections; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
 (ointments; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
 (sols.; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
 (suppositories; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
 (tablets, coated; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT Drug delivery systems
 (tablets; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT 175449-82-8, Matrix metalloproteinase 13 329900-75-6, Cyclooxygenase 2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT 449210-07-5 449210-13-3 449210-20-2
 449210-24-6 449210-27-9 449210-47-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib, and therapeutic use)
- IT 449210-07-5 449210-20-2 449210-24-6
 449210-27-9 449210-47-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(allosteric carboxylic inhibitor of matrix metalloproteinase-13
combination with selective inhibitor of cyclooxygenase-2 that is not
celecoxib or valdecoxib, and therapeutic use)


RN 449210-07-5 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-
1-methyl-2,4-dioxypyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA
INDEX NAME)




RN 449210-20-2 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-
1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester
(9CI) (CA INDEX NAME)




RN 449210-24-6 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-
1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA
INDEX NAME)



RN 449210-27-9 HCAPLUS


CN Pyrido[3,4-d]pyrimidine-6-carboxamide, 3-[[[(4-cyanophenyl)methyl]-1,2,3,4-
tetrahydro-N-[[[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA
INDEX NAME)



RN 449210-47-3 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-
1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA
INDEX NAME)

INDEX NAME)



L26 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:60302 HCAPLUS
 DN 140:105333
 ED Entered STN: 26 Jan 2004
 TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib, pharmaceutical compositions, and therapeutic use
 IN Roark, William Howard
 PA Warner-Lambert Company LLC, USA
 SO PCT Int. Appl., 238 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-415
 ICS A61K031-44; A61K031-42; A61K031-519
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006912	A2	20040122	WO 2003-IB3044	20030707
WO 2004006912	A3	20040603		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004019053	A1	20040129	US 2003-619662	20030715
PRAI US 2002-396903P	P	20020717		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004006912	ICM	A61K031-415
	ICS	A61K031-44; A61K031-42; A61K031-519

OS MARPAT 140:105333

AB The invention provides a combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. The invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase 2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of

MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.


- ST allosteric carboxylic inhibitor matrix metalloproteinase 13 celecoxib valdecoxib therapeutic; MMP13 allosteric carboxylic inhibitor celecoxib valdecoxib combination therapeutic
- IT Ampuls
- Analgesics
- Anti-inflammatory agents
- Antiarthritics
- Antirheumatic agents
- Drug delivery systems
- Human
- Inflammation
- Osteoarthritis
- Pain
- Rheumatoid arthritis
 - (allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
 - (capsules; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Cartilage, disease
 - (damage; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
 - (injections; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
 - (ointments; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Arthritis
 - (psoriatic arthritis; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
 - (solns.; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
 - (suppositories; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
 - (tablets, coated; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
 - (tablets; allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)
- IT 175449-82-8, Matrix metalloproteinase 13
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (allosteric carboxylic inhibitor of matrix metalloproteinase-13 combination with celecoxib or valdecoxib, pharmaceutical compns., and therapeutic use)

IT 169590-42-5, Celecoxib 181695-72-7, Valdecoxib 449210-07-5
449210-13-3 449210-20-2 449210-24-6
449210-27-9 449210-47-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(allosteric carboxylic inhibitor of matrix metalloproteinase-13
combination with celecoxib or valdecoxib, pharmaceutical compns., and
therapeutic use)

IT 449210-07-5 449210-20-2 449210-24-6
449210-27-9 449210-47-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(allosteric carboxylic inhibitor of matrix metalloproteinase-13
combination with celecoxib or valdecoxib, pharmaceutical compns., and
therapeutic use)


RN 449210-07-5 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-
1-methyl-2,4-dioxypyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA
INDEX NAME)




RN 449210-20-2 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-
1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester
(9CI) (CA INDEX NAME)




RN 449210-24-6 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-
1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA
INDEX NAME)




RN 449210-27-9 HCAPLUS

CN Pyrido[3,4-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-
tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA
INDEX NAME)



RN 449210-47-3 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)



L26 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:637660 HCAPLUS

ON 137:185501

ED Entered STN: 23 Aug 2002

TI Preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease

IN Andrianjara, Charles; Chantel-Barvian, Nicole; Gaudilliere, Bernard; Jacobelli, Henri; Ortwine, Daniel Fred; Patt, William Chester; Pham, Ly; Kostlan, Catherine Rose; Wilson, Michael William

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 264 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D239-96

ICS C07D401-12; C07D405-12; C07D409-12; C07D405-14; C07D409-14;

C07D471-04; C07D403-12; C07D403-10; C07D410-10; C07D413-10;

C07D401-06; A61K031-5025; A61K031-505

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064572	A1	20020822	WO 2002-EP1979	20020211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2437122	AA	20020822	CA 2002-2437122	20020211
	EP 1368324	A1	20031210	EP 2002-722137	20020211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300384	A	20031215	EE 2003-384	20020211
	JP 2004523546	T2	20040805	JP 2002-564505	20020211



US 2002193377	A1	20021219	US 2002-75954	20020213
NO 2003003593	A	20030813	NO 2003-3593	20030813
PRAI US 2001-268661P	P	20010214		
WO 2002-EP1979	W	20020211		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002064572	ICM	C07D239-96
	ICS	C07D401-12; C07D405-12; C07D409-12; C07D405-14; C07D409-14; C07D471-04; C07D403-12; C07D403-10; C07D410-10; C07D413-10; C07D401-06; A61K031-5025; A61K031-505
JP 2004523546	FTERM	4C063/AA01; 4C063/AA03; 4C063/BB03; 4C063/BB06; 4C063/BB08; 4C063/BB09; 4C063/CC31; 4C063/CC47; 4C063/CC58; 4C063/CC81; 4C063/CC92; 4C063/DD12; 4C063/DD28; 4C063/DD31; 4C063/EE01; 4C065/AA04; 4C065/AA05; 4C065/BB11; 4C065/CC01; 4C065/DD03; 4C065/EE02; 4C065/HH08; 4C065/JJ01; 4C065/KK01; 4C065/KK09; 4C065/LL04; 4C065/PP03; 4C065/PP07; 4C065/PP12; 4C065/QQ04; 4C065/QQ05; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC46; 4C086/BC62; 4C086/BC71; 4C086/BC73; 4C086/CB09; 4C086/GA07; 4C086/GA08; 4C086/GA09; 4C086/GA12; 4C086/MA01; 4C086/MA02; 4C086/MA03; 4C086/MA04; 4C086/MA05; 4C086/NA14; 4C086/ZA15; 4C086/ZA33; 4C086/ZA36; 4C086/ZA45; 4C086/ZA67; 4C086/ZA68; 4C086/ZA96; 4C086/ZA97; 4C086/ZB15; 4C086/ZB26; 4C086/ZC20; 4C086/ZC41; 4C086/ZC52

OS CASREACT 137:185501; MARPAT 137:185501

GI



AB Title compds. I [R1 = H, amino, alkyl, alkenyl, alkynyl, alkylamino, aryl, heterocycle, etc.; W = O, S, =N-R'; R' = alkyl, OH, CN; X1-3 = N, C-R6; R6 = H, alkyl, amino, alkylamino, etc.; Y = O, S, NH, N-alkyl; Z = O, S, NR7; R7 = H, alkyl, aryl, aryl, heteroaryl, etc.; n = 1-8; Z1 = alkyl; A = (non)aromatic, 5- or 6-membered monocycle comprising from 0 to 4 heteroatoms selected from N, O, S, etc.; m = 0-7; R2 = alkyl, halo, CN, NO2, SCF3, CF3, OCF3, etc.; R3 = H, alkyl, alkenyl, alkynyl, etc.] were prepared Over 200 synthetic examples were provided. For instance, di-Me 4-aminoisophthalate was reacted with benzylisocyanate and heated to 95-100.degree. overnight to give Me 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylate which was saponified (dioxaneaq. LiOH, reflux) to give the carboxylic acid. This intermediate was coupled with benzylamine to afford II. Selected examples of I had IC50 = 2.25 - 0.001 .mu.M for MMP13 and IC50 > 100 .mu.M for MMP1, MMP2, MMP3, MMP7, MMP9.

- MMP12 and MMP14: II had $IC_{50} = 0.193 \mu M$ for MMP13. Compds. I are useful for the treatment of osteoarthritis and rheumatoid arthritis.
- ST quinazoline mmp matrix metalloprotease inhibitor prepn
- IT Antiarteriosclerotics
(antiatherosclerotics; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Lung, disease
(chronic obstructive; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Heart, disease
(failure; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Intestine, disease
(inflammatory; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Eye, disease
(macula, senile degeneration; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Antiarthritics
Antiasthmatics
Antirheumatic agents
Antitumor agents
Arthritis
Asthma
Atherosclerosis
Human
Multiple sclerosis
Neoplasm
Osteoarthritis
Osteoporosis
Periodontium, disease
Psoriasis
Rheumatoid arthritis
(preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT Multiple sclerosis
Osteoporosis
(therapeutic agents; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
- IT 449208-02-0P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-pyridylmethyl)amide 449208-14-4P 449208-50-8P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-52-0P, Methyl 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449208-55-3P, 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449208-57-5P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449208-82-6P 449209-00-1P, [4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]acetic acid 449209-16-9P, Methyl 3-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-18-1P, (E)-Methyl 4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]but-2-enoate 449209-20-5P, Methyl 5-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]furan-2-carboxylate 449209-22-7P, Methyl 5-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]thiophene-2-carboxylate 449209-24-9P 449209-37-4P, Methyl 2-chloro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-43-2P, Methyl 2-methoxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-44-3P, 2-Methoxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-45-4P, Methyl 2-hydroxy-4-[[6-(4-

methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoate 449209-47-6P, Methyl 2-methyl-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoate 449209-49-8P 449209-52-3P 449209-54-5P, Methyl 4-[[6-(3-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoate 449209-60-3P, 4-[[1-Methyl-6-((4-methylsulfonyl)benzyl)carbamoyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoic acid methyl ester 449209-70-5P, 3-(4-Methoxybenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449209-75-0P, Methyl 4-[[1-methyl-2,4-dioxo-6-[(pyridin-4-yl)methyl]carbamoyl]-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoate 449209-89-6P 449209-90-9P 449209-91-0P 449209-95-4P 449209-98-7P, [5-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]pyridin-2-yl]carbamic acid tert-butyl ester 449210-36-0P, 4'-[[6-((4-Methoxybenzyl)carbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]biphenyl-2-carboxylic acid methyl ester 449210-88-2P, tert-Butyl 1-[4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]phenyl]cyclopropanecarboxylate 449210-90-6P, 3-Benzyl-6-benzylsulfonyl-1-methyl-1H-quinazoline-2,4-dione 449210-98-4P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazoline-3-yl)methyl]benzoic acid chloromethyl ester 449210-99-5P 449211-01-2P 474663-15-5P, Ethyl 2-Fluoro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)methyl]benzoate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(MMP13 inhibitor; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

- IT 449208-01-9P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-03-1P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide 449208-04-2P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (2-thienylmethyl)amide 449208-06-4P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (3-pyridylmethyl)amide 449208-07-5P 449208-08-6P 449208-09-7P 449208-10-0P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide 449208-11-1P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-12-2P, Methyl 4-[[[1-(3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)methanoyl]amino]methyl]benzoate 449208-13-3P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [4-hydroxy-3-methoxybenzyl]amide 449208-15-5P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-pyridylmethyl)amide 449208-16-6P, 1-Methyl-2,4-dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-20-2P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-22-4P, 3-(4-Methoxybenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-23-5P 449208-25-7P, 3-(1-(Naphth-1-yl)ethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-26-8P, 2,4-Dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-32-6P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-36-0P, 1-Methyl-2,4-dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzylamide 449208-37-1P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-38-2P, 1-Methyl-2,4-dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-39-3P, 3-(4-Chlorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-40-6P,

3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-41-7P,
 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-42-8P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-46-2P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-47-3P,
 3-Benzyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-48-4P, 3-Benzyl-1-cyclopropylmethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-49-5P,
 3-Benzyl-1-isobutyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-56-4P,
 1-Methyl-2,4-dioxo-3-((E)-3-phenylpropenyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-58-6P,
 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449208-59-7P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-pyridylmethyl ester 449208-60-0P 449208-61-1P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [Benzo[1,3]dioxol-5-yl]methyl ester 449208-62-2P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [Benzo[1,3]dioxol-5-yl]methyl ester 449208-63-3P, 1-Benzyl-2,4-dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449208-64-4P,
 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-Pyridylmethyl ester 449208-65-5P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 4-Pyridylmethyl ester 449208-66-6P, Benzyl 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylate 449208-67-7P,
 3-Benzyl-6-methyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione 449208-69-9P, 4-Pyridylmethyl 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylate 449208-70-2P, 3-Benzyl-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-71-3P, 4-[[6-(4-Hydroxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449208-72-4P
 449208-73-5P 449208-74-6P 449208-75-7P 449208-76-8P 449208-77-9P
 449208-78-0P 449208-79-1P 449208-80-4P 449208-81-5P 449208-83-7P
 449208-84-8P 449208-85-9P 449208-87-1P 449208-88-2P 449208-89-3P
 449208-90-6P 449208-91-7P 449208-92-8P 449208-93-9P, Ethyl
 [6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]acetate 449208-94-0P 449208-95-1P, Methyl 3-[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]propionate 449208-96-2P, 3-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]propionic acid 449208-97-3P
 449208-98-4P, 4-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]butyric acid 449208-99-5P, Methyl
 [4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]acetate 449209-01-2P 449209-02-3P
 449209-04-5P 449209-06-7P 449209-07-8P 449209-09-0P 449209-13-6P
 449209-14-7P 449209-17-0P, 3-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-19-2P,
 4-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]but-2-enoic acid 449209-21-6P, 5-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]furan-2-carboxylic acid 449209-23-8P, 5-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]thiophene-2-carboxylic acid 449209-25-0P 449209-26-1P
 449209-27-2P 449209-28-3P 449209-29-4P 449209-30-7P 449209-31-8P
 449209-32-9P 449209-33-0P 449209-34-1P 449209-36-3P 449209-39-6P,
 2-Chloro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-40-9P 449209-41-0P
 449209-46-5P, 2-Hydroxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-48-7P.

2-Methyl-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-53-4P 449209-59-0P, 4-[[6-(3-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-61-4P, 4-[[1-Methyl-6-(4-methylsulfanylbenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-62-5P, 4-[[1-Methyl-2,4-dioxo-6-(4-(trifluoromethoxy)benzylcarbamoyl)-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid methyl ester 449209-63-6P, Methyl 4-[[6-(4-fluorobenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-64-7P, 4-[[6-(4-Fluorobenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-65-8P, Methyl 4-[[6-[(benzofurazan-5-ylmethyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-66-9P, 4-[[6-[(Benzofurazan-5-ylmethyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-67-0P, Methyl 4-[[6-(4-methoxybenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-68-1P, Methyl 4-[[1-ethyl-6-(4-methoxybenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-69-2P, 4-[[1-Ethyl-6-(4-methoxybenzylcarbamoyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-71-6P, 3-(4-Hydroxybenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449209-72-7P, 3-(4-Cyanobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449209-74-9P, 1-Methyl-2,4-dioxo-3-(3-(pyridin-4-yl)propenyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449209-76-1P, 4-[[1-Methyl-2,4-dioxo-6-[(pyridin-4-ylmethyl)carbamoyl]-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid hydrochloride 449209-77-2P, Methyl [4-[[1-methyl-2,4-dioxo-6-[(pyridin-4-ylmethyl)carbamoyl]-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]acetate 449209-78-3P, [4-[[1-Methyl-2,4-dioxo-6-[(pyridin-4-ylmethyl)carbamoyl]-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]acetic acid hydrochloride 449209-79-4P 449209-80-7P 449209-81-8P, Methyl [6-[(1,3-Benzodioxol-5-ylmethyl)carbamoyl]-3-benzyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-1-yl]acetate 449209-82-9P, [6-[(1,3-Benzodioxol-5-ylmethyl)carbamoyl]-3-benzyl-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl]acetic acid 449209-83-0P, Methyl 4-[[6-[(1,3-benzodioxol-5-ylmethyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoate 449209-84-1P, 4-[[6-[(1,3-Benzodioxol-5-ylmethyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449209-85-2P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-(sulfamoyl)benzyl)amide 449209-86-3P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [3-(pyridin-4-ylsulfany)propyl]amide 449209-87-4P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-morpholin-4-ylbutyl)amide 449209-88-5P 449209-92-1P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-((dimethylcarbamoyl)methoxy)benzyl)amide 449209-93-2P 449209-94-3P 449209-96-5P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-(dimethylcarbamoyl)benzyl)amide 449209-97-6P 449209-99-8P 449210-00-8P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449210-01-9P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449210-03-1P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449210-07-5P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoic acid 449210-11-1P 449210-12-2P 449210-13-3P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449210-20-2P, Methyl 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoate 449210-23-5P, tert-Butyl

4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoate 449210-24-6P,
 4-[[6-(3-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoic acid 449210-27-9P
 449210-28-0P, 3-Benzyl-1-methyl-6-(3-phenylpropionyl)-1H-quinazoline-2,4-dione 449210-29-1P 449210-30-4P 449210-31-5P, 3-Benzyl-1-methyl-6-[2-(pyridin-4-ylsulfanyl)acetyl]-1H-quinazoline-2,4-dione 449210-32-6P
 449210-33-7P 449210-34-8P 449210-37-1P, 4'-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]biphenyl-2-carboxylic acid 449210-39-3P, 2-Fluoro-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449210-40-6P, 2-Methoxy-4-[[6-(4-methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 2-dimethylaminoethyl ester 449210-41-7P,
 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]-2-methylbenzoic acid 2-dimethylaminoethyl ester 449210-42-8P 449210-43-9P, [4-[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]phenyl]acetic acid 449210-45-1P,
 1-Methyl-3-(1-(naphthalen-1-yl)ethyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449210-47-3P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoic acid 449210-49-5P, 3-(3-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449210-51-9P, 3-(3-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-52-0P, 3-(3-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-3-yl)methyl)amide 449210-53-1P 449210-54-2P 449210-55-3P,
 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449210-56-4P,
 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-3-yl)methyl)amide 449210-57-5P 449210-61-1P,
 3-(4-Bromobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-62-2P,
 3-(3,4-Difluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridin-3-ylmethyl)amide 449210-66-6P,
 3-(3,4-Difluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridin-4-ylmethyl)amide 449210-67-7P 449210-68-8P,
 3-(3-Chloro-4-fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449210-72-4P 449210-73-5P 449210-74-6P 449210-75-7P 449210-76-8P,
 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449210-78-0P,
 3-(4-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-4-yl)methyl)amide 449210-79-1P,
 3-(4-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-3-yl)methyl)amide 449210-81-5P,
 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((pyridin-3-yl)methyl)amide 449210-82-6P 449210-84-8P 449210-85-9P, 3-(4-Fluorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-87-1P, 3-(4-Chlorobenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-89-3P, 1-[4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]cyclopropane carboxylic acid 449210-92-8P, 3-Benzyl-1-methyl-6-((phenylmethyl)sulfonyl)-1H-quinazoline-2,4-dione 449210-93-9P,
 3-Benzyl-1-methyl-6-((phenylmethyl)sulfonyl)-1H-quinazoline-2,4-dione 449210-94-0P 449210-95-1P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazoline-3-yl]methyl]benzoic acid, 3-(dimethylamino)-2,2-dimethylpropyl ester 449210-96-2P,
 4-[[6-((4-Methoxybenzyl)carbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazoline-3-yl]methyl]benzoic acid 2-(dimethylamino)-2-methylpropyl

ester 449210-97-3P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 2-dimethylaminoethyl ester 449211-00-1P 449211-04-5P 449211-08-9P 449211-12-5P, 4-[[6-((3-Methoxybenzylcarbamoyl)methyl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid methyl ester 449211-14-7P, 4-[[1-Ethyl-2,4-dioxo-6-((4-(trifluoromethoxy)benzyl)carbamoyl)-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid methyl ester 449211-16-9P, 4-[[1-Methyl-2,4-dioxo-6-((pyridin-4-ylmethyl)carbamoyl)-1,4-dihydro-2H-quinazolin-3-yl]methyl]benzoic acid 449211-18-1P, [4-[[1-Methyl-2,4-dioxo-6-((pyridin-4-ylmethyl)carbamoyl)-1,4-dihydro-2H-quinazolin-3-yl]methyl]phenyl]acetic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MMP13 inhibitor; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT 4315-09-7P, 4-Nitroisophthalic acid 23965-06-2P, 3-Benzyl-6-bromo-1H-quinazoline-2,4-dione 33857-88-4P 63746-12-3P, Dimethyl 4-aminoisophthalate 69048-70-0P, Dimethyl 4-nitroisophthalate 69209-73-0P 151979-21-4P, 5-Iodo-2-((methyl)amino)benzoic acid 177913-48-3P, Dimethyl 4-amino-1-hydroxycyclohexa-3,5-diene-1,3-dicarboxylate 184681-83-2P, 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 209604-61-5P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 221540-53-0P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 342644-48-8P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 449207-91-4P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449207-92-5P 449207-93-6P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carbonitrile 449207-94-7P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449207-95-8P, 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449207-96-9P, 1-Methyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449207-97-0P, 3-(3-Fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449207-98-1P, 1-Methyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449207-99-2P, 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-00-8P, 1-Ethyl-3-(3-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-17-7P, 2,4-Dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-18-8P, 2,4-Dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-19-9P, 2,4-Dioxo-3-phenethyl-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid [benzo[1,3]dioxol-5-ylmethyl]amide 449208-21-3P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-24-6P, 3-(4-Methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (4-methoxybenzyl)amide 449208-27-9P, Dimethyl 4-(N'-((pyridin-4-yl)methyl)ureido)isophthalate 449208-29-1P, 2,4-Dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-31-5P, 2,4-Dioxo-3-((pyridin-4-yl)methyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-33-7P 449208-34-8P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-35-9P, 2,4-Dioxo-3-(thien-2-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-43-9P 449208-44-0P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-45-1P, 3-((Benzo[1,3]dioxol-5-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449208-51-9P, 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449208-53-1P 449208-68-8P, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 449209-10-3P, 3-(4-Chlorosulfonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-11-4P,

3-(4-Dimethylsulfamoylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-12-5P.
 3-(4-Dimethylsulfamoylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-15-8P.
 1-Methyl-3-(4-methylsulfamoylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-50-1P.
 2,4-Dioxo-1-methyl-3-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449209-51-2P.
 2,4-Dioxo-1-methyl-3-(pyridine-4-ylmethyl)-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-55-6P.
 3-(4-Methoxycarbonylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449209-57-8P.
 3-(4-Methoxycarbonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid benzyl ester 449209-58-9P.
 3-(4-Methoxycarbonylbenzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-73-8P.
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridin-4-ylmethyl)amide 449210-02-0P.
 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid 449210-04-2P
 449210-05-3P 449210-06-4P.
 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 449210-08-6P.
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid 449210-09-7P 449210-10-0P.
 Methyl 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoate 449210-14-4P.
 1-Benzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxaldehyde 449210-15-5P
 449210-16-6P 449210-17-7P 449210-18-8P.
 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid methyl ester 449210-19-9P.
 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid 449210-21-3P.
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylic acid 449210-22-4P
 449210-25-7P 449210-26-8P.
 tert-Butyl 4-[[6-(3-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoate 449210-58-6P.
 3-(4-Bromobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-59-7P.
 1-Methyl-3-(4-bromobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-60-0P.
 1-Methyl-3-(4-bromobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449210-63-3P.
 3-(3,4-Difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-64-4P.
 1-Methyl-3-(3,4-difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-65-5P.
 1-Methyl-3-(3,4-difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449210-69-9P.
 3-(3-Chloro-4-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-70-2P.
 1-Methyl-3-(3-chloro-4-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid methyl ester 449210-71-3P.
 1-Methyl-3-(3-chloro-4-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449210-77-9P.
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridazin-4-ylmethyl)amide 449210-80-4P.
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid (pyridin-3-ylmethyl)amide 449210-83-7P 449210-86-0P.
 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid ((2-methoxypyridin-4-yl)methyl)amide 449210-91-7P.
 3-Benzyl-6-iodo-1-methyl-1H-quinazoline-2,4-dione

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate: preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT 9001-12-1, MMP-1 9004-06-2, MMP-12 79955-99-0, MMP 3 141256-52-2, MMP 7 146480-35-5, MMP-2 146480-36-6, MMP-9 161384-17-4, MMP-14 175449-82-8, MMP-13

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

IT 78-73-9, Choline bicarbonate 78-77-3, Isobutyl bromide 79-07-2, 2-Chloroacetamide 96-32-2, Methyl bromoacetate 96-33-3, Methyl acrylate 100-11-8, 4-Nitrobenzyl bromide 100-44-7, Benzyl chloride, reactions 100-46-9, Benzylamine, reactions 100-51-6, Benzyl alcohol, reactions 104-84-7, 4-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine 105-36-2, Ethyl bromoacetate 105-39-5, Ethyl 2-chloroacetate 106-95-6, Allyl bromide, reactions 106-96-7, Prop-2-ynyl bromide 108-00-9, N,N-Dimethylethylene diamine 108-01-0, 2-(Dimethylamino)ethanol 119-68-6, N-Methylantranilic acid 138-39-6, 4-(Aminomethyl)benzenesulfonamide 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl acrylate 332-48-9, 2-(4-Fluorophenoxy)ethyl bromide 351-52-0, 4-Chloromethyl-2-fluoro-1-methoxybenzene 459-46-1 495-76-1, Piperonyl alcohol 540-51-2, 2-Bromoethanol 586-95-8, 4-Pyridylcarbinol 593-71-5, Chloriodomethane 622-78-6, Benzyl isothiocyanate 622-95-7, 4-Chlorobenzyl bromide 637-59-2, 3-Phenylpropyl bromide 870-63-3, 1-Bromo-3-methylbut-2-ene 874-89-5, 4-Hydroxymethylbenzonitrile 874-98-6, 3-(Bromomethyl)-1-methoxyphenyl 938-09-0, 2-Chloroethyl phenyl sulfone 1117-71-1, Methyl 4-bromocrotonate 1129-28-8, Methyl 3-(bromomethyl)benzoate 1943-82-4, Phenethyl isocyanate 2144-37-8, Methyl 5-(chloromethyl)-2-furoate 2393-23-9, 4-Methoxybenzylamine 2417-72-3, Methyl 4-(bromomethyl)benzoate 2550-36-9, (Bromomethyl)cyclohexane 2620-50-0, Piperonylamine 2969-81-5, Ethyl 4-bromobutyrate 3113-72-2, 5-Methyl-2-nitrobenzoic acid 3173-56-6, Benzyl isocyanate 3277-89-2, Phenethylmagnesium bromide 3395-91-3, Methyl 3-bromopropanoate 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1, 4-Picolylamine 4070-48-8 4637-24-5 5071-96-5, 3-Methoxybenzylamine 5586-89-0 5794-88-7, 2-Amino-5-bromobenzoic acid 6232-11-7, Methyl 4-(aminomethyl)benzoate hydrochloride 6321-07-9, 4-Morpholin-4-ylbutylamine 6482-24-2, 1-Bromo-2-methoxyethane 7005-47-2, 2-(Dimethylamino)-2-methylpropanol 7051-34-5, Cyclopropylmethyl bromide 7149-10-2, 4-Hydroxy-3-methoxybenzylamine hydrochloride 7398-42-7, Methyl 4-(bromomethyl)phenylacetate 10406-25-4 13734-41-3 17201-43-3, 4-(Bromomethyl)benzonitrile 18469-52-8, Methyl 4-aminomethyl benzoate 19059-68-8, 3-(Dimethylamino)-2,2-dimethylpropanol 22059-22-9, N-Hydroxyacetamide 22600-30-2, Methyl 5-amino-2-furan carboxylate 25589-18-8, 3-Benzyl-6-methyl-1H-pyrimidine-2,4-dione 26146-77-0, (E)-Cinnamyl bromide 27757-85-3, 2-Thienylmethylamine 28188-41-2, 3-(Bromomethyl)benzonitrile 30260-66-3, Dimethylhydrazine 30280-44-5, 4-Chlorobenzyl isocyanate 32863-31-3, 5-Bromomethylbenzofurazan 39077-96-8 40724-47-8, 4-Bromomethylbenzenesulfonamide 41886-04-8, 3-Bromomethyl-1-methylpiperidine 50541-93-0, 4-Amino-1-benzylpiperidine 55401-97-3, 2-(Bromomethyl)pyridine 56651-60-6, 4-Methoxybenzyl isocyanate 69966-55-8, 3-(Bromomethyl)pyridine 72235-53-1, 3,4-Difluorobenzylamine 72235-56-4, 3-Chloro-4-fluorobenzylamine 74733-27-0, Methyl 4-bromomethyl-2-methoxybenzoate 74733-28-1, Methyl 4-bromomethyl-2-methyl benzoate 78358-86-8, 1-(2-Bromoethyl)pyrrole 78826-46-7, (tert-Butoxy)acetyl chloride 83171-39-5, 4-Methylthiobenzylamine 85070-57-1, Methyl 4-(bromomethyl)-2-fluorobenzoate 85147-14-4 88442-63-1, 1-(1-Naphthyl)ethyl isocyanate 89583-07-3, 4-(2-Bromoethyl)morpholine 93919-56-3, 4-Trifluoromethoxybenzylamine 99067-96-6, (4-(Dimethylamino)benzyl)isocyanate 102422-56-0, 3-Fluorobenzyl isocyanate 108052-76-2, tert-Butyl 4-bromomethylbenzoate 108499-32-7, Methyl 5-bromomethylthiophene-2-carboxylate 114772-38-2 114772-54-2, 2-(4-Bromomethylphenyl)benzonitrile 120788-70-7, Ethyl 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylate 128674-45-3, 4-(3-Chloropropenyl)pyridine hydrochloride 138402-33-2 138895-24-6, 6-Amino-3-benzyl-1H-pyrimidine-2,4-dione 148900-69-0 154470-79-8, Methyl 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-6-carboxylate 155965-45-0 220875-89-8, 5-(4-Chloromethylphenyl)-1-methyl-1H-tetrazole 221031-44-3, 2-Chloro-1-(4-diethylaminophenyl)ethan-1-one 302912-23-8, 4-Bromobenzyl isocyanate 304873-96-9, tert-Butyl (5-bromomethylpyridin-2-yl)carbamate 448965-87-5, tert-Butyl 1-(4-bromomethylphenyl)cyclopropanecarboxylate

449208-54-2. 1-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-03-4. 3-((E)-3-Chloropropenyl)pyridine 449209-05-6, 4-((E)-3-Chloropropenyl)pyridine 449209-08-9. 3-(4-(Methanesulfonyl)benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carboxylic acid 449209-35-2. 3-(4-Chloromethylphenyl)-5-methyl[1,2,4]oxadiazole 449209-38-5. Methyl 2-chloro-4-chloromethylbenzoate 449209-42-1. 5-(4-Chloromethylphenyl)-2-methyl-2H-tetrazole 449209-56-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Abou-Hadeed, K; PTERIDINES 1996, V7(4), P113 HCAPLUS
- (2) Anon; AMBINTER: EXPLORATORY LIBRARY 2002
- (3) Anon; CHEMSTAR PRODUCT LIST 2001
- (4) Anon; SCIENTIFIC EXCHANGE PRODUCT LIST 2001
- (5) Anon; SCREENING COLLECTION 2000
- (6) Bemis, G; WO 9964400 A 1999 HCAPLUS
- (7) Brittelli, D; WO 9743239 A 1997 HCAPLUS
- (8) Chen, J; JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 2000, V122, P9648 HCAPLUS
- (9) Ciba Geigy Ag; DE 2441959 A 1975 HCAPLUS
- (10) Ghose, A; J MED CHEM 1984, V27(7), P901 HCAPLUS
- (11) Kim, Y; CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON PTERIDINES AND FOLATES, 11TH 1997, P41 MEDLINE
- (12) Lespagnol, A; BULL SOC PHARM LILLE 1977, V33(1), P67 HCAPLUS
- (13) Liverton, N; BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1998, V8(5), P483 HCAPLUS
- (14) Murata, S; CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON PTERIDINES AND FOLATES, 11TH 1997, P17 HCAPLUS
- (15) Nesterov; SU 119879 A 1959 HCAPLUS
- (16) Ogawa, H; CHEM PHARM BULL 1988, V36(6), P2253 HCAPLUS
- (17) Reiter, L; BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1999, V9(2), P127 HCAPLUS
- (18) Sladowska, H; FARMACO, ED SCI 1986, V41(12), P954 HCAPLUS


IT 449210-07-5P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoic acid 449210-11-1P 449210-20-2P, Methyl 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoate 449210-24-6P, 4-[[6-(3-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoic acid 449210-27-9P 449210-47-3P, 4-[[6-(4-Methoxybenzylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-3-yl]methyl]benzoic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MMP13 inhibitor; preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)


RN 449210-07-5 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 449210-11-1 HCAPLUS

CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 449210-20-2 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 449210-24-6 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, (9CI) (CA INDEX NAME)




RN 449210-27-9 HCAPLUS

CN Pyrido[3,4-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 449210-47-3 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, (9CI) (CA INDEX NAME)



IT 449210-10-0P, Methyl 4-[[6-(4-Methoxybenzyl)carbamoyl]-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate: preparation of quinazolines as specific inhibitors of type-13 matrix metalloprotease)
 RN 449210-10-0 HCAPLUS
 CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



L26 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:637472 HCAPLUS
 DN 137:201321
 ED Entered STN: 23 Aug 2002
 TI Preparation of substituted isophthalic acid derivatives, multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors
 IN Andrianjara, Charles; Ortwine, Daniel Fred; Pavlovsky, Alexander Gregory; Roark, William Howard
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl., 173 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064080	A2	20020822	WO 2002-IB447	20020213
WO 2002064080	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437643	AA	20020822	CA 2002-2437643	20020213
US 2003078276	A1	20030424	US 2002-75069	20020213

EP 1361873	A2	20031119	EP 2002-710275	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007864	A	20040309	BR 2002-7864	20020213
JP 2004529874	T2	20040930	JP 2002-563877	20020213
US 2005004126	A1	20050106	US 2004-835619	20040429
PRAI US 2001-268821P	P	20010214		
US 2002-75069	B3	20020213		
WO 2002-IB447	W	20020213		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002064080	ICM	A61K
JP 2004529874	FTERM	4C022/CA02; 4C036/AD05; 4C036/AD12; 4C036/AD19; 4C036/AD27; 4C036/AD30; 4C050/AA01; 4C050/AA07; 4C050/BB06; 4C050/CC08; 4C050/EE04; 4C050/FF03; 4C050/GG03; 4C050/HH02; 4C055/AA01; 4C055/BB01; 4C055/CA01; 4C055/DA06; 4C055/DA17; 4C055/DB04; 4C055/DB08; 4C055/EA01; 4C063/AA01; 4C063/AA03; 4C063/BB08; 4C063/BB09; 4C063/CC31; 4C063/CC81; 4C063/CC92; 4C063/DD12; 4C063/DD31; 4C063/EE01; 4C065/AA04; 4C065/BB11; 4C065/CC01; 4C065/DD03; 4C065/EE03; 4C065/HH08; 4C065/JJ01; 4C065/LL04; 4C065/PP18; 4C071/AA01; 4C071/BB01; 4C071/CC21; 4C071/EE13; 4C071/FF05; 4C071/GG02; 4C071/HH08; 4C071/HH28; 4C071/JJ01; 4C071/LL01; 4C072/AA01; 4C072/BB02; 4C072/CC02; 4C072/CC16; 4C072/EE12; 4C072/FF09; 4C072/GG07; 4C072/GG09; 4C072/HH02; 4C072/UU01; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BA13; 4C086/BC17; 4C086/BC46; 4C086/BC87; 4C086/CB05; 4C086/CB09; 4C086/CB26; 4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA10; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA02; 4C086/ZA36; 4C086/ZA45; 4C086/ZA59; 4C086/ZA67; 4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB11; 4C086/ZB15; 4C086/ZB26; 4H006/AA01; 4H006/AA03; 4H006/AB20; 4H006/AB22; 4H006/AB23; 4H006/AB25; 4H006/AB27; 4H006/AB28; 4H006/BJ50; 4H006/BM30; 4H006/BM71; 4H006/BM72; 4H006/BP30; 4H006/BR30; 4H006/BT32; 4H006/BU26; 4H006/BV72; 4H006/KC30
US 2005004126	ECLA	A61K031/00; C07D213/30D2; C07D213/40B; C07D239/96; C07D285/14D; C07D285/24; C07D317/54; C07D317/58; C07D401/06+239+211; C07D401/06+239+213; C07D401/12+239+213; C07D405/12+317+213; C07D405/12+317+239; C07D405/14+317+239+213; C07D405/14+317+317+239; C07D409/06+333B+239; C07D409/12+333B+239; C07D409/14+333B+239+213; C07D409/14+333B+317+239; C07D471/04+239B+221B; C07D487/04+235C+239C; C07D487/04+249C+239C; C07D495/04+333B+239B; C07D513/04+277C+239C

GI



- AB Title compds., I [R1 and R2 together may form a substituted aromatic ring or a heterocyclic ring; or R2 and R3 together may form substituted heterocycle; or R1, R3, or R4 = alkyl, arylalkyl, etc.; X = C, S; Y = O, N with provision when Y = N it forms a 5-membered heterocycle with R3] and II [R5, R6 = arylalkylamine, heterocyclalkoxy, etc.; R7 = H, MeO, NO₂, etc.], are prepared and disclosed as matrix metalloproteinase (MMP) inhibitors. Thus, III was prepared in five steps via cyclocondensation of diethylmalonate and benzylurea with subsequent chlorination, substitution with hydrosulfide hydrate to form an in situ intermediate that was reacted with bromoacetaldehyde dimethylacetal, followed by acid catalyzed cyclization and substitution with benzylchloroformate. III was demonstrated to inhibit MMP13 with an IC₅₀ value (in .mu.M) of 0.0230. I and II bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond resp. with Thr245, Thr247 and Met 253, the first hydrophobic group locates within the S1' channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compds. specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.
- ST pyrimidinedione prepn matrix metalloproteinase inhibitor; isophthalic carboxylate prepn matrix metalloproteinase inhibitor; metalloproteinase inhibitor pyrimidinedione antiinflammatory
- IT Antiarteriosclerotics
(antiatherosclerotics; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Lung, disease
(chronic obstructive; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Heart, disease
(failure; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Intestine, disease
(inflammatory; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Combinatorial library
(isophthalic acid derivs.; combinatorial preparation and pharmaceutical activity of substituted isophthalic acid derivs. as matrix metalloproteinase inhibitors)

- IT Eye, disease
(macula, senile degeneration; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antirheumatic agents
Antitumor agents
Arthritis
Asthma
Atherosclerosis
Cardiovascular agents
Human
Multiple sclerosis
Neoplasm
Osteoarthritis
Osteoporosis
Periodontium, disease
Psoriasis
Rheumatoid arthritis
(preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT Multiple sclerosis
Osteoporosis
(therapeutic agents; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT 449790-74-3P 449790-84-5P 449790-90-3P 449791-35-9P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(combinatorial preparation and pharmaceutical activity of substituted isophthalic acid derivs. as matrix metalloproteinase inhibitors)
- IT 1459-93-4P, Dimethyl isophthalate 4315-09-7P, 4-Nitroisophthalic acid 5759-76-2P 13756-42-8P, 4-Methylbenzoic acid tert-butyl ester 63746-12-3P, Dimethyl 4-aminoisophthalate 69048-70-0P, Dimethyl 4-nitroisophthalate 91360-95-1P 108052-76-2P, tert-Butyl-4-(bromomethyl)benzoate 175143-75-6P 177913-48-3P, Dimethyl 4-amino-1-hydroxycyclohexa-3,5-diene-1,3-dicarboxylate 209604-61-5P 221540-53-0P 342644-48-8P 448964-68-9P 448964-69-0P 448964-70-3P 449207-91-4P 449207-94-7P 449207-95-8P 449208-21-3P 449208-24-6P 449208-33-7P 449208-34-8P 449208-35-9P 449208-43-9P 449208-44-0P 449208-45-1P 449208-51-9P 449208-53-1P 449210-05-3P 449210-06-4P 449210-08-6P 449210-09-7P 449210-10-0P 449210-14-4P, 1-Benzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxaldehyde 449210-15-5P 449210-16-6P 449210-17-7P 449210-18-8P 449210-19-9P 449210-21-3P 449210-22-4P 449211-37-4P 449211-38-5P 449755-90-2P 449755-91-3P 449755-92-4P 449755-95-7P 449755-96-8P 449798-65-6P 449798-67-8P, 6-Benzylthiazolo[3,2-c]pyrimidine-5,7-dione 449798-69-0P 449798-70-3P 449798-72-5P 449798-74-7P 449799-51-3P 449799-52-4P 449799-63-7P 449799-64-8P 451471-59-3P 451471-60-6P 451471-61-7P 451471-62-8P 451471-63-9P 451471-64-0P 451471-65-1P 451471-66-2P 451471-67-3P 451471-68-4P 451471-69-5P 451471-70-8P 451471-71-9P 451471-72-0P 451471-73-1P 451471-74-2P 451471-75-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)
- IT 9001-12-1, Matrix metalloproteinase-1 79955-99-0, Matrix metalloproteinase-3 141256-52-2, Matrix metalloproteinase-7 146480-35-5, Matrix metalloproteinase-2 146480-36-6, Matrix

- metalloproteinase-9 161384-17-4, Matrix metalloproteinase-14
175449-82-8, Collagenase 3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)
- IT 149277-46-3, GenBank A0000434
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)
- IT 100-46-9, Benzyl amine, reactions 104-86-9, 4-Chlorobenzyl amine
2393-23-9, 4-Methoxybenzylamine 2620-50-0, Piperonyl amine
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial
study); RACT (Reactant or reagent)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)
- IT 449792-10-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)
- IT 96-33-3, Methyl acrylate 99-63-8, 1,3-Benzenedicarbonyl dichloride
100-11-8, 4-Nitrobenzylbromide 100-51-6, Benzyl alcohol, reactions
105-53-3, Diethylmalonate 108-90-7, Chlorobenzene, reactions 140-88-5,
Ethyl acrylate 459-46-1, 4-Fluorobenzyl bromide 495-76-1, Piperonyl
alcohol 501-53-1, Benzylchloroformate 538-32-9, Benzylurea 586-95-8,
4-Pyridinemethanol 609-08-5, Diethylmethyl malonate 623-51-8,
Mercapto-acetic acid, ethyl ester 874-60-2, 4-Methylbenzoyl chloride
1189-71-5, N-Chlorosulfonyl isocyanate 2206-43-1, 4-Methoxy-1,3-
benzenedicarboxylic acid 2417-72-3, Methyl-4-(bromomethyl)benzoate
3113-72-2, 5-Methyl-2-nitrobenzoic acid 3173-56-6, Benzylisocyanate
3731-53-1, Pyridin-4-ylmethylamine 4392-24-9, Cinnamyl bromide
4637-24-5 5326-47-6, 2-Amino-5-iodobenzoic acid 6232-11-7, Methyl
4-(aminomethyl)benzoate, hydrochloride 6959-47-3, Picolyl chloride,
hydrochloride 7149-10-2, 4-Hydroxy-3-methoxybenzylamine, hydrochloride
7252-83-7, Bromoacetaldehyde dimethylacetal 10147-11-2,
3-Phenyl-1-propyne 13235-60-4 13540-76-6, 3-(4-Methoxyphenyl)prop-1-
yne 17201-43-3, 4-(Bromomethyl)benzonitrile 18358-63-9,
Methyl-4-methylaminobenzoate 18469-52-8, Methyl 4-(aminomethyl)benzoate
22600-30-2, Methyl-5-amino-2-furoate 25589-18-8, 3-Benzyl-6-methyl-1H-
pyrimidine-2,4-dione 27757-85-3, 2-Thiophene methylamine 30280-44-5,
4-Chlorobenzyl isocyanate 40517-43-9, 4-Methylsulfonylbenzyl chloride
54751-01-8, 4-Bromomethylpyridine 56651-60-6, 4-Methoxybenzyl isocyanate
138895-24-6, 6-Amino-3-benzyl-1H-pyrimidine-2,4-dione 183741-86-8
305804-90-4 305805-20-3 449208-54-2 449211-43-2 449798-87-2
449799-49-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and pharmaceutical activity of substituted isophthalic acid
derivs., multicyclic pyrimidinediones and analogs thereof as matrix
metalloproteinase inhibitors)
- IT 449790-79-8P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(target compound; combinatorial preparation and pharmaceutical activity of
substituted isophthalic acid derivs. as matrix metalloproteinase
inhibitors)
- IT 448964-75-8P 449208-01-9P 449208-02-0P 449208-37-1P 449208-39-3P
449208-42-8P 449208-50-8P 449208-57-5P 449211-17-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(target compound; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)

IT	16034-14-3P	143569-91-9P	151107-61-8P	152699-63-3P	167993-08-0P
	349396-68-5P	383163-58-4P	448964-76-9P	448964-82-7P	448964-84-9P
	448964-85-0P	448964-86-1P	448964-90-7P	448964-94-1P	448964-98-5P
	448964-99-6P	448965-31-9P	448965-33-1P	448965-35-3P	448965-36-4P
	448965-38-6P	448965-39-7P	448965-41-1P	448965-42-2P	448965-43-3P
	448965-44-4P	448965-46-6P	448965-47-7P	448965-48-8P	448965-49-9P
	448965-50-2P	448965-51-3P	448965-57-9P	448965-58-0P	448965-59-1P
	448965-60-4P	448965-64-8P	448965-66-0P	448965-67-1P	448965-69-3P
	448965-70-6P	448965-71-7P	448965-72-8P	448965-73-9P	448965-74-0P
	448965-75-1P	448965-76-2P	448965-77-3P	448965-78-4P	448965-79-5P
	448965-80-8P	448965-82-0P	448965-89-7P	448965-91-1P	448965-93-3P
	448965-96-6P	448965-97-7P	448965-98-8P	448965-99-9P	448966-00-5P
	448966-01-6P	448966-02-7P	448966-03-8P	448966-04-9P	448966-05-0P
	448966-06-1P	448966-07-2P	448966-09-4P	448966-10-7P	448966-11-8P
	448966-12-9P	448966-13-0P	448966-14-1P	448966-15-2P	448966-16-3P
	448966-17-4P	448966-19-6P	448966-21-0P	448966-22-1P	448966-23-2P
	448966-24-3P	448966-25-4P	448966-26-5P	448966-27-6P	448966-28-7P
	448966-29-8P	448966-30-1P	448966-31-2P	448966-32-3P	448966-33-4P
	448966-34-5P	448966-35-6P	448966-36-7P	448966-42-5P	448966-45-8P
	448966-50-5P	448966-52-7P	448966-53-8P	448966-57-2P	448966-65-2P
	448966-68-5P	448966-71-0P	448966-72-1P	448966-75-4P	448966-77-6P
	448966-78-7P	448966-85-6P	448966-86-7P	448966-87-8P	448966-88-9P
	448966-92-5P	448966-94-7P	448966-95-8P	448966-96-9P	448966-97-0P
	448967-02-0P	448967-05-3P	448967-06-4P	448967-07-5P	448967-08-6P
	448967-09-7P	448967-10-0P	448967-12-2P	448967-13-3P	448967-14-4P
	448967-16-6P	448967-19-9P	448967-20-2P	448967-21-3P	448967-23-5P
	448967-24-6P	448967-25-7P	448967-26-8P	448967-27-9P	448967-28-0P
	448967-29-1P	448967-30-4P	448967-31-5P	448967-34-8P	448967-35-9P
	448967-38-2P	448967-39-3P	448967-41-7P	448967-44-0P	448967-45-1P
	448967-47-3P	448967-48-4P	448967-49-5P	448967-50-8P	448967-52-0P
	448967-53-1P	448967-54-2P	448967-56-4P	448967-57-5P	448967-59-7P
	448967-60-0P	448967-61-1P	448967-63-3P	448967-64-4P	448967-66-6P
	448967-69-9P	448967-71-3P	448967-72-4P	448967-73-5P	448967-74-6P
	448967-76-8P	448967-80-4P	448967-81-5P	448967-82-6P	448967-87-1P
	448967-88-2P	448967-92-8P	448967-93-9P	448967-94-0P	448967-96-2P
	448967-97-3P	448967-98-4P	448967-99-5P	448968-00-1P	448968-03-4P
	448968-11-4P	448968-12-5P	448968-16-9P	448968-19-2P	448968-23-8P
	448968-24-9P	448968-27-2P	448968-28-3P	448968-30-7P	448968-34-1P
	448968-35-2P	448968-40-9P	448968-41-0P	448968-43-2P	448968-44-3P
	448968-45-4P	448968-49-8P	448968-51-2P	448968-53-4P	448968-54-5P
	448968-55-6P	448968-68-1P	448968-69-2P	448970-24-9P	449208-03-1P
	449208-04-2P	449208-06-4P	449208-07-5P	449208-08-6P	449208-09-7P
	449208-10-0P	449208-11-1P	449208-12-2P	449208-13-3P	449208-14-4P
	449208-15-5P	449208-16-6P	449208-20-2P	449208-22-4P	449208-23-5P
	449208-26-8P	449208-32-6P	449208-36-0P	449208-38-2P	449208-40-6P
	449208-41-7P	449208-46-2P	449208-47-3P	449208-48-4P	449208-49-5P
	449208-52-0P	449208-55-3P	449208-58-6P	449208-59-7P	449208-60-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)

IT	449208-61-1P	449208-62-2P	449208-63-3P	449208-64-4P	449208-65-5P
	449208-66-6P	449208-69-9P	449208-70-2P	449208-71-3P	449208-72-4P
	449208-73-5P	449208-74-6P	449208-75-7P	449208-76-8P	449208-77-9P
	449208-78-0P	449208-79-1P	449208-80-4P	449208-81-5P	449208-82-6P
	449208-83-7P	449208-84-8P	449208-85-9P	449208-87-1P	449208-88-2P

449208-89-3P 449208-90-6P 449208-91-7P 449208-92-8P 449208-93-9P
 449208-94-0P 449208-95-1P 449208-96-2P 449208-97-3P 449208-98-4P
 449208-99-5P 449209-00-1P 449209-01-2P 449209-06-7P 449209-07-8P
 449209-09-0P 449209-13-6P 449209-14-7P 449209-16-9P 449209-17-0P
 449209-18-1P 449209-19-2P 449209-20-5P 449209-21-6P 449209-22-7P
 449209-23-8P 449209-24-9P 449209-25-0P 449209-26-1P 449209-27-2P
 449209-28-3P 449209-29-4P 449209-30-7P 449209-31-8P 449209-32-9P
 449209-33-0P 449209-34-1P 449209-36-3P 449209-37-4P 449209-39-6P
 449209-40-9P 449209-41-0P 449209-43-2P 449209-44-3P 449209-45-4P
 449209-46-5P 449209-47-6P 449209-48-7P 449209-49-8P 449209-52-3P
 449209-53-4P 449209-54-5P 449209-59-0P 449209-60-3P 449209-61-4P
 449209-63-6P 449209-64-7P 449209-65-8P 449209-66-9P 449209-67-0P
 449209-68-1P 449209-69-2P 449209-70-5P 449209-71-6P 449209-72-7P
 449209-75-0P 449209-77-2P 449209-79-4P 449209-81-8P 449209-82-9P
 449209-83-0P 449209-84-1P 449209-86-3P 449209-89-6P 449209-90-9P
 449209-91-0P 449209-94-3P 449209-97-6P 449209-98-7P 449209-99-8P
 449210-00-8P 449210-01-9P 449210-03-1P 449210-07-5P
 449210-11-1P 449210-12-2P 449210-13-3P 449210-20-2P
 449210-24-6P 449210-27-9P 449210-28-0P 449210-29-1P
 449210-30-4P 449210-31-5P 449210-32-6P 449210-33-7P 449210-34-8P
 449210-36-0P 449210-37-1P 449210-38-2P 449210-39-3P 449210-40-6P
 449210-41-7P 449210-42-8P 449210-45-1P 449210-47-3P
 449210-49-5P 449210-51-9P 449210-52-0P 449210-53-1P 449210-54-2P
 449210-55-3P 449210-56-4P 449210-57-5P 449210-61-1P 449210-62-2P
 449210-66-6P 449210-67-7P 449210-68-8P 449210-72-4P 449210-74-6P
 449210-75-7P 449210-76-8P 449210-78-0P 449210-79-1P 449210-81-5P
 449210-82-6P 449210-84-8P 449210-85-9P 449210-87-1P 449210-88-2P
 449210-89-3P 449210-90-6P 449210-95-1P 449210-96-2P 449210-97-3P
 449211-02-3P 449211-03-4P 449211-04-5P 449211-05-6P 449211-06-7P
 449211-07-8P 449211-08-9P 449211-09-0P 449211-10-3P 449211-11-4P
 449211-13-6P 449211-14-7P 449211-15-8P 449211-16-9P 449211-18-1P
 449211-19-2P 449211-20-5P 449211-21-6P 449211-22-7P 449211-24-9P
 449211-25-0P 449211-27-2P 449211-28-3P 449211-29-4P 449211-30-7P
 449211-31-8P 449211-32-9P 449211-33-0P 449211-34-1P 449211-35-2P
 449211-36-3P 449754-49-8P 449754-50-1P 449754-51-2P 449754-53-4P
 449754-59-0P 449754-61-4P 449754-62-5P 449754-64-7P 449754-65-8P
 449754-66-9P 449754-67-0P 449754-69-2P 449754-70-5P 449754-72-7P
 449754-73-8P 449754-74-9P 449754-75-0P 449754-76-1P 449754-77-2P
 449754-78-3P 449754-79-4P 449754-80-7P 449754-82-9P 449754-83-0P
 449754-84-1P 449754-85-2P 449754-86-3P 449754-87-4P 449754-88-5P
 449754-89-6P 449754-97-6P 449754-99-8P 449790-17-4P 449790-22-1P
 449790-25-4P 449790-28-7P 449790-33-4P 449790-36-7P 449790-39-0P
 449790-42-5P 449790-45-8P 449790-52-7P 449790-57-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(target compound: preparation and pharmaceutical activity of substituted
 isophthalic acid derivs., multicyclic pyrimidinediones and analogs
 thereof as matrix metalloproteinase inhibitors)

IT 449790-60-7P 449790-66-3P 449790-70-9P 449790-87-8P 449790-95-8P
 449790-98-1P 449791-01-9P 449791-04-2P 449791-09-7P 449791-12-2P
 449791-15-5P 449791-18-8P 449791-20-2P 449791-28-0P 449791-31-5P
 449791-41-7P 449791-44-0P 449791-47-3P 449791-50-8P 449791-53-1P
 449791-56-4P 449791-59-7P 449791-62-2P 449791-65-5P 449791-68-8P
 449791-71-3P 449791-74-6P 449791-77-9P 449791-81-5P 449791-84-8P
 449791-90-6P 449791-93-9P 449791-96-2P 449791-99-5P 449792-02-3P
 449792-04-5P 449792-07-8P 449792-13-6P 449798-64-5P 449798-68-9P
 449798-71-4P 449798-75-8P 449798-80-5P 449798-81-6P 449798-82-7P
 449798-86-1P 449798-88-3P 449798-90-7P 449798-91-8P 449798-94-1P
 449798-95-2P 449798-97-4P 449799-02-4P 449799-05-7P 449799-06-8P
 449799-14-8P 449799-16-0P 449799-19-3P 449799-27-3P 449799-34-2P
 449799-36-4P 449799-37-5P 449799-38-6P 449799-40-0P 449799-42-2P
 449799-43-3P 449799-44-4P 449799-45-5P 449799-50-2P 449799-53-5P
 449799-55-7P 449799-58-0P 449799-59-1P 449799-60-4P 449799-62-6P

449799-65-9P 449799-66-0P 449799-67-1P 449799-70-6P 449799-71-7P
 449799-72-8P 449799-73-9P 449799-74-0P 449799-76-2P 449799-77-3P
 449799-78-4P 449799-79-5P 449799-80-8P 449799-81-9P 449799-84-2P
 449799-85-3P 449799-86-4P 449799-87-5P 449799-89-7P 449799-90-0P
 449799-93-3P 449799-96-6P 449799-97-7P 449799-98-8P 449800-01-5P
 449800-03-7P 449800-04-8P 449800-05-9P 449800-07-1P 449800-08-2P
 449800-09-3P 449800-12-8P 449800-13-9P 449800-15-1P 449800-19-5P
 451471-31-1P 451471-32-2P 451471-33-3P 451471-34-4P 451471-35-5P
 451471-36-6P 451471-37-7P 451471-38-8P 451471-39-9P
 Thieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester 451471-40-2P
 451471-41-3P 451471-42-4P 451471-43-5P 451471-44-6P 451471-45-7P
 451471-47-9P 451471-48-0P 451471-49-1P 451471-50-4P 451471-51-5P
 451471-52-6P 451471-53-7P 451471-54-8P 451471-55-9P 451471-56-0P
 451471-57-1P 451471-58-2P 451473-18-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(target compound; preparation and pharmaceutical activity of substituted
 isophthalic acid derivs., multicyclic pyrimidinediones and analogs
 thereof as matrix metalloproteinase inhibitors)

IT 452379-12-3

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(unclaimed protein sequence; preparation and pharmaceutical activity of
 substituted isophthalic acid derivs., multicyclic pyrimidinediones and
 analogs thereof as matrix metalloproteinase inhibitors)


IT 449210-10-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation and pharmaceutical activity of substituted
 isophthalic acid derivs., multicyclic pyrimidinediones and analogs
 thereof as matrix metalloproteinase inhibitors)

RN 449210-10-0 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-
 1-methyl-2,4-dioxypyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester
 (9CI) (CA INDEX NAME)



IT 449210-07-5P 449210-11-1P 449210-20-2P


449210-24-6P 449210-27-9P 449210-47-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(target compound; preparation and pharmaceutical activity of substituted
 isophthalic acid derivs., multicyclic pyrimidinediones and analogs
 thereof as matrix metalloproteinase inhibitors)


RN 449210-07-5 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-
 1-methyl-2,4-dioxypyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA
 INDEX NAME)




RN 449210-11-1 HCAPLUS

CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 449210-20-2 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 449210-24-6 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 449210-27-9 HCAPLUS

CN Pyrido[3,4-d]pyrimidine-6-carboxamide, 3-[(4-cyanophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 449210-47-3 HCAPLUS

CN Benzoic acid, 4-[[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxypyrido[3,4-d]pyrimidin-3(2H)-yl]methyl]- (9CI) (CA
INDEX NAME)



=> b home

FILE 'HOME' ENTERED AT 13:44:45 ON 07 FEB 2005

=>